Identification of 64 new risk loci for major depression, refinement of the genetic

2 architecture and risk prediction of recurrence and comorbidities

- 4 Thomas D. Als^{1,2,3}, Mitja Kurki⁴, Jakob Grove^{1,2,3,5}, Georgios Voloudakis^{6,7,8,9,10,11}, Karen
- Therrien^{6,7,8,9,10,11,12}, Elisa Tasanko¹³, Trine Tollerup Nielsen^{1,2,3}, Joonas Naamanka¹³, Kumar 5
- Veerapen^{14,15,16}, Daniel Levey^{17,18}, Jaroslav Bendl^{6,7,8,9,10}, Jonas Bybjerg-Grauholm^{2,19}, Biao 6
- Zheng^{6,7,8,9,10}, Ditte Demontis^{1,2,3}, Anders Rosengren^{2,20}, Georgios Athanasiadis^{2,20}, Marie Bækved-7
- Hansen^{2,19}, Per Qvist^{1,2,3}, Bragi Walters²¹, Thorgeir Thorgeirsson²¹, Hreinn Stefánsson²¹, Katherine L Musliner^{2,22,23,24}, Veera Manikandan^{1,2,3}, Leila Farajzadeh^{1,2,3}, Janne Thirstrup^{1,2,3}, Bjarni J. 8
- 9
- Vilhjálmsson^{2,5,25}, John J. McGrath^{25,26,27}, Manuel Mattheisen², Sandra Meier², iPSÝCH-Broad 10
- Consortium, Esben Agerbo^{2,22,23}, Kári Stefánsson²¹, Merete Nordentoft^{2,28}, Thomas Werge^{2,20}, David 11
- M. Hougaard^{2,19}, Preben B. Mortensen^{2,22,23}, Murray Stein^{29,30}, Joel Gelernter^{17,18}, Iiris Hovatta¹³, 12
- Panos Roussos^{6,7,8,9,10,11,31}, Mark J. Daly^{4,14,15,16}, Ole Mors^{2,32}, Aarno Palotie⁴, and Anders D. 13
- 14 Børglum^{1,2,3}

1

3

15

- ¹ Department of Biomedicine, Aarhus University, Aarhus, Denmark 16
- 17 ² The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Denmark
- 18 ³ Center for Genomics and Personalized Medicine, Aarhus, Denmark
- 19 ⁴ Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland
- 20 ⁵ Bioinformatics Research Centre, Aarhus University, 8000 Aarhus C, Denmark
- 21 ⁶ Center for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, NY, USA
- 22 ⁷ Department of Psychiatry, Icahn School of Medicine at Mount Sinai, NY, USA
- 23 ⁸ Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New
- 24 York, NY, USA
- 25 ⁹ Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount
- 26 Sinai, NY, USA
- 27 ¹⁰ Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 28 ¹¹ Mental Illness Research, Education, and Clinical Center (VISN 2 South), James J. Peters VA
- 29 Medical Center, Bronx, NY, USA
- 30 ¹² Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York,
- 31 NY, USA
- 32 ¹³ Department of Psychology and Logopedics, SleepWell Research Program, University of Helsinki,
- 33
- 34 ¹⁴ Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital
- 35 and Harvard Medical School, Boston, MA, USA
- 36 ¹⁵ Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA,
- 37
- 38 ¹⁶ Department of Medicine, Harvard Medical School, Boston, MA, USA
- 39 ¹⁷ Division of Human Genetics, Department of Psychiatry, Yale University School of Medicine, New
- 40 Haven, CT, USA
- 41 ¹⁸ Department of Psychiatry, Veterans Affairs Connecticut Healthcare Center, West Haven, CT, USA
- 42 ¹⁹ Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum Institut,
- 43 Copenhagen, Denmark
- 44 ²⁰ Mental Health Centre Sct. Hans, Capital Region of Denmark, Institute of Biological Psychiatry,
- 45 Copenhagen University Hospital, Copenhagen, Denmark
- 46 ²¹ deCODE genetics / Amgen, Reykjavik, Iceland
- 47 ²² NCRR - National Centre for Register-Based Research, Business and Social Sciences, Aarhus
- 48 University, Aarhus, Denmark
- 49 ²³ Centre for Integrated Register-based Research, CIRRAU, Aarhus University, Aarhus, Denmark
- 50 ²⁴ Department of Affective Disorders, Aarhus University Hospital-Psychiatry, Aarhus Denmark
- 2NOTE This preprint reports new research based bearing that has been retified by per review and, should not be used to print reports new research. 51

²⁶ Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Brisbane, QLD

2 4076, Australia

1

14

15

- 3 ²⁷ Queensland Brain Institute, University of Queensland, Brisbane, QLD 4072, Australia
- 4 ²⁸ Mental Health Centre Copenhagen, Capital Region of Denmark, Copenhagen University Hospital,
- 5 Copenhagen, Denmark
- 6 ²⁹ Psychiatry Service, VA San Diego Healthcare System, San Diego, CA, USA
- 7 ³⁰ Departments of Psychiatry and Herbert Wertheim School of Public Health, University of California,
- 8 San Diego, La Jolla, CA, USA
- ³¹ Center for Dementia Research, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 9
- 10 10962, USA
- 11 ³² Psychosis Research Unit, Aarhus University Hospital-Psychiatry, Denmark
- 12 Corresponding authors: Thomas D Als tda@biomed.au.dk and Anders D Børglum
- 13 anders@biomed.au.dk

Abstract

- 16 Major depression (MD) is a common mental disorder and a leading cause of disability
- 17 worldwide. We conducted a GWAS meta-analysis of more than 1.3 million individuals,
- including 371,184 with MD, identifying 243 risk loci. Sixty-four loci are novel, including 18
- 19 glutamate and GABA receptors that are targets for antidepressant drugs. Several biological
- 20 pathways and components were enriched for genetic MD risk, implicating neuronal
- 21 development and function. Intersection with functional genomics data prioritized likely
- 22 causal genes and revealed novel enrichment of prenatal GABAergic neurons, astrocytes and
- 23 oligodendrocyte lineages.
- 24 We found MD to be highly polygenic, with around 11,700 variants explaining 90% of the
- 25 SNP heritability. Bivariate Gaussian mixture modeling estimated that > 97% of risk variants
- for other psychiatric disorders (anxiety, schizophrenia, bipolar disorder and ADHD) are 26
- 27 influencing MD risk when both concordant and discordant variants are considered, and nearly
- 28 all MD risk variants influence educational attainment. Additionally, we demonstrated that
- 29 MD genetic risk is associated with impaired complex cognition, including verbal reasoning,
- 30 attention, abstraction and mental flexibility.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Analyzing Danish nation-wide longitudinal data, we dissected the genetic and clinical heterogeneity, revealing distinct polygenic architectures across case subgroups of MD recurrency and psychiatric comorbidity and demonstrating two- to six-fold increases in absolute risks for developing comorbid psychiatric disorders among MD cases with the highest versus the lowest polygenic burden. The results deepen the understanding of the biology underlying MD and its progression and inform precision medicine approaches in MD. Introduction Major depression (MD) is a genetic and phenotypic complex disorder with a lifetime prevalence of 15-20% ¹⁻³. It is often recurrent and accompanied by considerable morbidity and co-morbidity, excess mortality, increased risk of suicide and substantial costs worldwide⁴⁻⁸. Individuals diagnosed with MD have an increased risk of developing practically all other types of mental disorders, particularly anxiety (ANX), bipolar disorder (BD), schizophrenia (SZ) and substance use disorder $(SUD)^{9,10}$. Heritability estimates based on twin studies ($h^2 = 0.37$) have indicated that familial aggregation of MD is influenced by additive genetic effects¹¹, and several recent studies have documented a considerable genetic overlap between MD and multiple psychiatric as well as somatic disorders and traits¹²⁻¹⁷. Despite the substantial heritability of MD and other mental disorders, the potential for translating genetic insights into precision psychiatry has yet to be fulfilled, including demonstrating clinical utility of polygenic risk scores (PRS)¹⁸⁻²⁰. Major advancement in understanding the genetic architecture of MD has only recently been achieved, primarily via genome-wide association studies (GWAS) led by the Psychiatric Genomics Consortium (PGC). Most recently, GWAS results from the PGC¹², UK Biobank

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

(UKB)^{14,21}, FinnGen and 23andMe, Inc.²² were combined with data from the Million Veteran Program (MVP) in a large meta-analysis²³, identifying 178 risk loci. The identified loci explain a small fraction of the overall heritability of MD^{12,21,23} and even larger GWASs are needed to further elucidate genetic factors contributing to the risk of developing MD and advance genetically informed patient stratification and outcome prediction towards clinical utility. Here, we present the largest MD GWAS to date, including expanded iPSYCH²⁴ and FinnGen cohorts, meta-analyzed with PGC, UKB, 23 and Me and MVP data²³, revealing numerous novel risk loci and characterizing functional implications of associated variants by intersecting with functional genomics data. We refine the genetic architecture of MD and case subgroups, and demonstrate the impact of MD genetic risk on domains of cognitive performance. Leveraging nation-wide longitudinal health data on the Danish iPSYCH cohort, we dissect the genetic architecture of single-episode and recurrent MD as well as cases who have developed ANX, BD, SZ and SUD. Furthermore, to inform precision psychiatry approaches, we calculate time-dependent absolute risks and hazard rate ratios for developing recurrent depression, ANX, BP, SZ and SUD depending on different polygenic burdens of MD cases. **Results** *Genome-wide association* We analyzed data from the large population-based case-cohort of iPSYCH^{24,25}, which include genotypes from all individuals born in Denmark between 1981 and 2008 who have received treatment for MD in hospitals and outpatient clinics (ICD-10 codes F32-F33 in the Danish Psychiatric Central Research Register²⁶). Compared to the latest GWAS of MD²³, which included samples from the initial iPSYCH2012 cohort^{12,25}, we added 11,710 cases and 18,410

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

controls from the expanded iPSYCH2015 cohort^{24,25}, summarizing to a total of 30,618 cases and 38,200 controls after relatedness pruning and removal of ancestry outliers. In addition, we included an updated dataset consisting of 28,098 cases and 228,817 controls from the FinnGen study. When combining these with data from previously published samples from the PGC, UKB, 23andMe and MVP, the number of samples added up to a total of 371,184 MD cases and 978,703 controls (Supplementary Table S1). We performed a variance weighted fixed effects meta-analysis using METAL²⁷, testing the effects of 6,037,120 SNPs common across all the data sets. This revealed a total of 303 genome-wide significant LD-independent ($r^2 < 0.1$) lead variants located in 243 distinct loci. A conditional association analysis using GCTA-COJO^{28,29} retained 251 independent SNPs in the 243 loci. Manhattan plots are shown in Figure 1, regional plots are provided in Supplementary Figure S2 and details on lead variants are provided in Supplementary Table S2A, while GCTA-COJO independent variants are listed in Supplementary Table S2B. No statistically significant heterogeneity was observed between the datasets (Supplementary Figure S3). Sixty-four (64) of the 243 loci are novel, i.e., not overlapping with the two most recent MD meta-analyses 14,23 (Supplementary Table S2A). The three most significant loci were located near NEGR1, in SORCS3 and in the HIST1 histone cluster, respectively. Among the novel loci, the three strongest associations were in *BPTF*, *LINGO1* and *GRIA1* (Table 1). All three genes have been associated with monogenic forms of neurodevelopmental disorders³⁰⁻³² and *GRIA1*, encoding glutamate ionotropic receptor AMPA type subunit 1 (GluA1), is the first genome-wide significant locus implicating an AMPA receptor subunit in MD. We also note that the seventh-strongest novel locus is located in *GABRA1*, which is the first time a GABA receptor locus has been identified in GWAS of MD. Both AMPA and GABA receptors are targets for antidepressants^{33,34}.

1 Genetic correlations and heritability

- 2 Analyzing the GWAS meta-analysis by LD score regression (LDsc)³⁵ produced a genomic
- inflation factor (λ_{GC}) estimate of 1.89 with an intercept of 1.06 (SE = 0.01) and an 3
- 4 attenuation ratio of 0.047 (SE = 0.012), indicating that 95% of the observed inflation of the
- 5 test statistics (Supplementary Figure S1) is due to polygenic signal rather than population
- structure. The individual GWASs (iPSYCH2015, Howard et al. 2019¹⁴, Wray et al. 2018¹², 6
- 7 Levey et al. 2020²³ and FinnGen) showed significant pairwise genetic correlations, ranging
- from $r_G = 0.77$ to $r_G = 0.95$ (Supplementary Table S4 and Figure S6), thus corroborating 8
- 9 that the GWAS results are combined in a meta-analysis. We note that the SNP-heritability
- estimate³⁵ for the iPSYCH cohort ($h_{SNP}^2 = 0.167$, SE = 0.014, prevalence = 0.2) was 10
- 11 significantly higher (around double) compared to the other cohorts (Supplementary Table S5
- 12 and Figure S7). This may reflect that the iPSYCH sample is more homogeneous and includes
- 13 relatively severe cases who have been treated in hospitals.

14

- We investigated genetic correlations with other phenotypes available at LD Hub³⁶ and in-15
- 16 house, including published GWASs (N = 258) and GWAS results for UKB traits (N = 597).
- 17 MD was significantly correlated ($P < 2 \times 10^{-4}$) with 364 phenotypes representing several
- domains and overall confirming previous observations^{12-15,37-42} (Supplementary Table S6A 18
- 19 and Figure S8A). Among psychiatric disorders, MD showed significant correlation with e.g.,
- ADHD ($r_G = 0.56$, SE = 0.022, P = 1 x 10⁻¹³⁵), autism spectrum disorder (ASD) ($r_G = 0.35$, 20
- SE = 0.033, $P = 6.5 \times 10^{-24}$), $BP (r_G = 0.31, SE = 0.033, P = 3 \times 10^{-18})$, $SZ (r_G = 0.33, SE = 0.033, P = 0.033, P = 0.033)$ 21
- 0.021, P = 4 x 10^{-53}), ANX ($r_G = 0.79$, SE = 0.017, P = 3.2×10^{-193}), alcohol dependence (r_G 22
- 23 = 0.65, SE = 0.097, P = 4.3 x 10^{-9}) and cannabis use disorder (r_G = 0.44, SE = 0.036, P = 2.2
- x 10⁻³¹). In UKB data, the three strongest genetic correlations were seen for "Seen doctor 24

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

(GP) for nerves anxiety tension or depression", "Mood swings" and "Miserableness" ($r_G =$ 0.96, 0.71, 0.71, respectively; Supplementary Table S6B and Figure S8B). To dissect the observed genetic overlap further, we used uni- and bivariate gaussian mixture modeling, as implemented in MiXeR⁴³, to quantify the actual number of variants that (i) explain 90% of the SNP heritability of MD, and (ii) overlap between MD and MD-correlated phenotypes. Approximately 11,700 (SE = 310) common variants were estimated to confer liability to MD, suggesting that MD is the most polygenic of the major psychiatric disorders evaluated, showing number of risk variants ranging between 6-10,000^{43,44} (Figure 3, Supplementary Table S7). MiXeR considers all variants irrespective of the direction of correlation (i.e. both variants with same and opposite direction of effects, hereafter collectively referred to as "influencing" variants). Strikingly, the vast majority of variants conferring risk to the other psychiatric disorders investigated were found to influence MD (range 85-98%; Figure 3; Supplementary Table S7), most pronounced for ANX, SZ, BP and ADHD with 97-99% 44 of their risk variants also influencing MD. The other investigated traits showed also substantial overlap with MD (range 85-98%). Notably, the fraction of concordant variants within the shared part varied considerably; lowest for educational attainment (42%) and highest for SUD (88%) and ANX (90%). Association with cognitive performance Educational attainment was among the most prominent negatively correlated traits. To further evaluate the impact of MD genetic risk on cognition, we analyzed the association of MD polygenic scores (MD-PRS) with 15 cognitive measures in the Philadelphia Neurodevelopmental Cohort (PNC, N = 4,973)^{45,46}. Cognitive performance was measured by the Computerized Neurocognitive Battery⁴⁷, including 14 tests in 5 domains: executive-

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

control, episodic memory, complex cognitive processing, social cognition, and sensorimotor speed. In addition, the Wide Range Achievement Test (WRAT-4)⁴⁸ was used as a proxy measure for overall IQ⁴⁶. MD-PRS was negatively associated with attention ($\beta = -0.036$, SE = 0.012, P = 0.032) and abstraction and mental flexibility (β = -0.036, SE = 0.013, P = 0.032) in the executive-control domain, and verbal reasoning ($\beta = -0.029$, SE = 0.011, P = 0.032) in the reasoning domain, while e.g. the WRAT-4 test did not show association (Figure 2, Supplementary Table S8). The results demonstrate, for the first time, that genetic MD risk is associated with attenuated functioning in specific cognitive domains. This is consistent with observations that individuals suffering from MD show lower performance in cognitive domains such as executive function, memory, language and attention⁴⁹⁻⁵¹. *Gene-wise* and pathway analysis A genome-wide gene-based association study conducted in Multi-Marker Analysis of GenoMic Annotation (MAGMA)⁵², mapped the GWAS SNPs to 17,840 protein coding genes and revealed 411 genes significantly associated with MD after Bonferroni correction for the number of genes tested ($P < 2.8 \times 10^{-6}$). A total of 314 significant genes were located in 141 of the 242 identified GWAS loci, while the remaining 97 significant genes were located outside these loci (Supplementary Table S9D). The most significant gene within each of the 141 genomic risk loci are labeled in Figure 1B. To investigate enrichment of biological pathways we analyzed 8,664 gene-sets derived from GO Biological Process (N = 7,658) and GO Cellular Components (N = 1,006) ontology in the MSigDB database, identifying 479 significant gene-sets after correction for multiple testing (FDR < 0.05, Supplementary Table S10B), including several gene-sets that have not previously shown significant enrichment 14,23. The majority of the top-ranking sets related to neuronal development and function including the five most significant gene-sets (Padj <

1 10⁻¹⁴): GO SYNAPSE, GO NEURON PART, GO SYNAPSE ORGANIZATION, 2 GO SYNAPSE ASSEMBLY and GO NEURON DIFFERENTIATION. 3 4 Transcriptome-wide association and GWAS-eQTL prioritisation 5 To identify and prioritize putative causal genes, we performed a transcriptome-wide 6 association study (TWAS), imputing the genetically regulated gene expression using EpiXcan⁵³ and models trained on expression data from the PsychENCODE Consortium^{54,55} 7 8 for genes and isoforms detected in the dorsolateral prefrontal cortex (DLPFC). Among 9 34,646 transcripts (genes and isoforms) tested, we identified 2,541 transcripts at FDR < 0.05 10 and, after Bonferroni correction of all transcripts tested, 324 transcripts from 201 genes 11 showing significant differential imputed gene expression in DLPFC between MD cases and 12 controls (Supplementary Table S11). The Bonferroni significant transcripts were located in 88 independent⁵⁶ regions. The top gene/isoform is labeled in Figure 1A and regional 13 14 TWAS/GWAS Miami-plots for each of the 88 regions are shown in Figure S9. In 38 of the 15 88 regions, the top transcript was > 100 times more significant than the second-most 16 associated gene/isoform in the region (Supplementary Table S11B), appointing those as 17 plausible causal candidates. 18 To further prioritize likely causal genes and variants, we performed co-localization analyses 19 integrating fine-mapped GWAS results, using the CAUSALdb pipeline (Methods), and eQTL data from a meta-analysis of three brain datasets⁵⁷ applying a fixed-effect model. First, we 20 adopted the Coloc method^{58,59}, which revealed 13 genes with strong evidence for both 21 22 GWAS-association, eQTL-association and co-localization (i.e., with a posterior probability of 23 PPH4 > 0.8; Supplementary Table S12). The three top-ranked genes were: FURIN, NEGR1 24 and CKS2. Secondly, we conducted the eQTL and GWAS CAusal Variants Identification in Associated Regions (eCAVIAR) approach⁶⁰, in which both eQTL and GWAS were fine-

25

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

mapped and the product of posterior probability (CLPP) was calculated, prioritizing variants with at least a single variant with CLPP >= 0.01. The eCAVIAR approach revealed five prioritized variants located in three genes: FURIN, GPR27 and TCTA (Supplementary Table S13 and Figure S10). *Tissue and cell type enrichment* We next tested whether the GWAS results were enriched with respect to the transcriptomic profiles of human tissues. At the specific tissue level, we found significant enrichment exclusively in brain tissues, including all the brain tissues analyzed (Supplementary Figure S11). Cell-type enrichment analyses revealed experiment-wide significant association (across all 13 datasets tested) of primarily neuronal cell-types, including dopaminergic and GABAergic neurons (Supplementary Figure S12 and S13). Interestingly, both GABAergic neurons and oligodendrocyte progenitor cells of the human prefrontal cortex were enriched already at prenatal stages. To further evaluate cell-type enrichment, we intersected the GWAS results with two recent epigenomic maps of cell-specific open chromatin^{61,62} using an LD score partitioned heritability approach⁶³. Again, we observed a clear contrast between the enrichments in the brain and nonbrain tissue (Supplementary Figure S14). Consistent with our FUMA-based results and prior reports^{12,14}, the strongest associations were measured for neuronal cell types, phenotypically manifested by severe synaptic loss and deficits in functional connectivity^{64,65}. Conversely, to our knowledge, the reported association of MD with astrocytes and oligodendrocyte lineages have not yet been described by genetic data, albeit having support in behavioral and postmortem studies⁶⁶⁻⁶⁸. Polygenic architecture and co-morbidity rates for single-episode and recurrent depression

All rights reserved. No reuse allowed without permission.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

To dissect the polygenic architecture of single-episode and recurrent depression, we used dates of diagnosis in the Danish Psychiatric Central Research Register to group the 30,618 iPSYCH MD cases into 24,101 cases with single-episode and 6,517 with recurrent depression (see Methods and Supplementary Table S14 for details). We conducted three GWASs: 1) single-episode vs controls, 2) recurrent depression vs. controls and 3) recurrent vs. singleepisode depression (excluding all controls). SNP-heritability estimates were similar for recurrent and single-episode depression and, for the case-only analysis, not significantly different from zero (Supplementary Table S5 and Figure S7). Likewise, the genetic correlations with other phenotypes showed similar patterns for single-episode and recurrent depression (Supplementary Figure S15 and Table S15). We next investigated the polygenic load for MD in the recurrent and single-episode case groups, using a multivariate polygenic risk score (mvPRS) approach¹⁵ and the MD GWAS meta-analysis 14,23 without iPSYCH samples for training. This analysis showed significant association of single-episode ($\beta = 0.36$, SE = 0.0081, P < 10^{-7}) and recurrent ($\beta =$ 0.43, SE = 0.014, P < 10^{-7}) subgroups with PRS for MD (MD-PRS), but with a significantly larger effect size for recurrent than for single-episode depression ($P = 4.8 \times 10^{-6}$, Supplementary Table S16A and Figure S16A). This increased polygenic load among recurrent cases reinforces previous observations 11,12,69,70. To further dissect the genetic architecture of the two subgroups we investigated the PRS load for psychiatric disorders and traits showing strong genetic correlation with MD (Figure S16B-I, Table S16A) including ANX, BD, SZ, ASD, ADHD, SUD, substance use (SU) and neuroticism. The results showed an overall pattern of increased PRS among recurrent cases compared to single-episode cases (P = 0.00075), primarily driven by significantly different burdens of MD, ANX, BP and neuroticism PRS (Figure S16 and Table S16A).

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

To complement these analyses, we compared the rates of comorbid psychiatric disorders between single-episode and recurrent cases, using data from the Danish Psychiatric Central Research Register, and found highly significant increase in comorbidity among recurrent cases (Supplementary Table S17). This is consistent with well-established correlations between MD symptom severity, recurrence, chronicity and comorbidities (e.g. 10,71) and, to our knowledge, it is the first quantification of differences in psychiatric comorbidity rates between single-episode and recurrent case groups. The most compelling differences were observed for ANX, BP and SZ. Summarizing, compared to single-episode cases, recurrent cases showed significantly increased polygenic load of particularly MD-, BP- and neuroticism-PRS as well as increased rates of comorbid psychiatric disorders. Hazard rate ratio and absolute risk of recurrent depression To investigate whether PRS can prospectively predict recurrence among individuals with first-onset depression, we performed Cox regression analyses estimating hazard rate ratio (HRR) and absolute risk of developing a second episode of depression over time among individuals having a first diagnosis of MD. This was done for groups of increasing polygenic load, in PRS deciles. We found that the HRR of developing a second-episode generally increased with increasing MD-PRS, most significantly for the 10th MD-PRS decile compared to the first decile ($HRR_{10} = 1.33$, SE = 0.06, $P = 2.5 \times 10^{-6}$; Supplementary Figure S18A and Table S18). Similarly, the absolute risk of a second diagnosis of depression increased with time since first diagnosis for all MD-PRS deciles, with the trajectories for the 10th decile reaching an absolute risk of 0.35 compared to 0.24 for the lowest decile (Supplementary Figure S18A).

1 Prompted by the results of the mvPRS analysis, we performed the same analysis for PRSs 2 from other psychiatric disorders, but without yielding significant results (Figure S18, Table 3 S18). The HRR for developing single-episode and recurrent MD in the general population 4 can be found in Supplementary Figure S17. 5 Dissecting the polygenic architecture of psychiatric comorbidity among MD cases 6 7 Individuals diagnosed with MD are at an increased risk of developing other mental disorders as documented in Supplementary Table S17 and a large body of studies (e.g. 9,10,72), but little 8 9 is known about the genetic constitution of those that develop these conditions. We examined the polygenic architecture of MD cases who have developed ANX, BP, SZ and SUD, using 10 11 mvPRS analysis and PRSs from MD and eight psychiatric phenotypes genetically correlated 12 with MD (ANX, BD, SZ, ASD, ADHD, SUD, SU and neuroticism; Supplementary Table 13 S6A and Figure S8). This analysis showed that the subgroup of MD cases who had 14 transitioned to BP, had a significantly increased PRS for three out of the eight psychiatric 15 phenotypes tested compared to MD cases without a later BP diagnosis, including BP-PRS (P $= 5.2 \times 10^{-17}$), SZ-PRS (P = 3.2 x 10^{-12}) and MD-PRS (P = 8.3 x 10^{-5}) (Figure S19 (B), Table 16 17 S19B). MD cases with a co-diagnosis of SZ showed increased PRS load for all eight 18 psychiatric phenotypes except ASD (Figure S19 (C), Table S19C), most significantly for SZ-PRS (P = 2.9×10^{-14}), BP-PRS (P = 5.5×10^{-8}), substance use (SU) PRS (P = 2.4×10^{-5}) and 19 MD-PRS ($P = 2.5 \times 10^{-5}$). The most compelling results were revealed for SUD comorbidity, 20 21 showing highly increased PRS loads for most of the psychiatric phenotypes (Figure S19 (D), Table S19D), most significantly for SU-PRS ($P = 2.3 \times 10^{-84}$), ADHD-PRS ($P = 1.2 \times 10^{-31}$) 22 23 and SUD-PRS ($P = 2.4 \times 10^{-30}$).

have increased polygenic burdens of common risk variants for several psychiatric phenotypes

Overall, we demonstrated that all three comorbid subgroups (MD-BP, MD-SZ, MD-SUD)

24

25

1 compared to the non-comorbid MD (MD-only) case groups (overall mvPRS p-values: PMD-

- 2 $ANX = 1.2 \times 10^{-21}$, $P_{MD-BP} = 3.7 \times 10^{-16}$, $P_{MD-SZ} = 3.2 \times 10^{-14}$, $P_{MD-SUD} = 1 \times 10^{-93}$), revealing an
- 3 overall PRS pattern that distinguishes the comorbid case groups from their non-comorbid
- 4 counterparts. We also note that all three comorbid subgroups showed an increased load of
- 5 MD-PRS compared to the MD-only case groups.

6

22

- 7 Hazard rate ratio and absolute risk of comorbidity among MD cases
- 8 To assess the use of PRS in prediction of developing comorbid disorders, we performed Cox
- 9 regression analysis on MD cases with and without additional diagnosis of ANX, BP, SZ and
- 10 SUD, using the same eight PRSs as in the above-mentioned mvPRS analysis. In addition, we
- 11 included four aggregate scores combining all PRSs into a single score weighted by their
- 12 association with ANX, BP, SZ and SUD respectively (see Methods).
- 13 We found that the HRR for developing BP increased with increasing polygenic loads
- 14 (Supplementary Figure S21 and Table S20B), most significantly for BP-PRS (HRR₁₀ = 1.84,
- 15 SE = 0.12, $P = 9.3 \times 10^{-7}$) and the aggregate score (BP-SUM-PRS; HRR₁₀ = 2.32, SE = 0.14,
- $P = 7.5 \times 10^{-10}$) with the absolute risk trajectory reaching 0.11 for the 10th BP-SUM-PRS 16
- 17 decile compared to 0.04 for the 1st decile as shown in Figure 4.
- 18 A similar pattern was observed for MD cases developing SZ (Supplementary Figure S22,
- 19 Table S20C) where the highest HRR was seen for the aggregate SZ-SUM-PRS (HRR₁₀ =
- 20 1.82, SE = 0.11, P = 1 x 10^{-7}), with the absolute risk curve for the 10^{th} decile reaching 0.14,
- 21 well separated from the 1st decile trajectory approaching 0.067 (Figure 4).
- 23 The most striking results were obtained for SUD showing substantial differences in HHR and
- 24 absolute risk estimates across PRS deciles for several phenotypes (Supplementary Figure
- 25 S23, Table S20D). Again, the most significant prediction was obtained for the aggregate

SUD-SUM-PRS (HRR₁₀= 3.92, SE = 0.13, P = 3.6×10^{-27}) with the absolute risk trajectory reaching 0.17 at 15 years after first episode for the 10^{th} decile in contrast to the first decile reaching a maximum risk of 0.03 (Figure 4), indicating that the absolute risk for developing SUD is almost 6 times higher for the most genetically burdened (top decile) MD case group compared to the least burdened group in the lowest decile at 15 years after first episode.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

We performed an MD GWAS meta-analysis of more than 1.3 million individuals, identifying 251 independent risk variants in 243 genomic loci, of which 64 are novel. Among the novel loci, we highlight GRIA1 and GABRA1, encoding a glutamate AMPA receptor subunit (GluA1) and a GABA receptor subunit (α1), respectively. Neither of these two loci have previously been identified in GWAS of MD or other mental disorders (Supplementary Table S2). The two genes showed also significant imputed differential expression in the DLPFC (at Bonferroni and FDR<0.05 significance, respectively; Supplementary Table S11) in our TWAS. We note that another GABA receptor subunit gene, GABRB1, was also significant (at FDR < 0.05) in the TWAS (Supplementary Table S11). GABRB1, although not significantly associated with MD in the current GWAS, has previously been implicated in schizoaffective disorder⁷³ and SZ^{74,75}. Our pathway analysis reinforced previous reports^{12,14,23} and extended the enrichment of glutamatergic and GABAergic synapses and functions, further indicating that glutamatergic and GABAergic dysfunctions are key etiologic components in MD. Along with the observed enrichment of GABAergic cell-types present already prenatally, this supports the accumulating multidisciplinary evidence that implicate excitatory/inhibitory (E/I) imbalance with MD⁷⁶ as well as other psychiatric disorders⁷⁷⁻⁸⁰.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

Our TWAS found that GRIA1 expression in DLPFC was decreased in cases compared to controls. This is consistent with findings in preclinical pharmacological studies of mood disorders showing promising results of AMPA receptor potentiators³⁴, as well as the convergent rapid and sustained increase in GluA1 and other synaptic proteins associated with most fast-acting antidepressants³³. Thus, our results provide human genetic evidence that emphasizes positive modulation of the AMPA receptor as an interesting pharmacological approach. In contrast to a reported decrease in GABRA1 expression in the DLFPC of depressed suicide cases^{81,82}, our TWAS pointed to an increased expression in MD cases. GABA_A receptors provide critical inhibitory control of the firing of glutamatergic excitatory neurons and they are the binding partner of several drugs in mood disorders and potential drug targets for other mental disorders⁸³⁻⁸⁵. Inhibitory synapse formation depends on the expression and selective postsynaptic clustering of GABAA receptor subunits, which is a combinatorial process in which pentamers are assembled from nineteen different subunits ($\alpha 1$ -6, $\beta 1$ -3, $\gamma 1$ -3, δ , ϵ , π , and θ). The subunit composition varies according to brain region and neuronal subtype, and confers unique physiological and pharmacological properties. Cortical expression of GABRA1 increases drastically in the first few years of postnatal human development⁸⁶, and in the adult brain, all contributes to the majority of both synaptic and extra-synaptic GABAA receptors complexes. Antidepressant effects have been associated with pharmacological modulation of both synaptic⁸⁷ and, more promising, extra-synaptic GABA_A receptors⁸⁸. Although a recent study indicated that reversing the E/I imbalance alone only induces shortterm antidepressant effects, but not long-term clinical response⁸⁹, our findings support the use of pharmacological modulators of the $\alpha 1 \beta x \delta$ subset of extra-synaptic GABA_A complexes.

perpetuity.
All rights reserved. No reuse allowed without permission.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

The MiXeR bivariate Gaussian mixture modeling revealed compelling genetic overlap between MD and other traits when considering both concordant and discordant variants, suggesting that psychiatric disorders and correlated traits are substantially more intertwined than indicated by their genetic correlations. Perhaps the most surprising results were seen for educational attainment (EA), showing that 98% of the MD risk variants are also influencing EA and, vice-versa, 88% of EA variants are influencing MD. This almost complete overlap in influencing variants, with concordant (42% of the shared variants) and discordant effects, is consistent with the traits' overall negative genetic correlation ($r_G = -0.23$) and refines the understanding of their polygenic architecture appreciably. Although generally less pronounced, a similar picture was observed for the other mental and behavioural traits examined. Furthermore, the notable overlap suggests that future fine-mapping efforts to pinpoint the causal variants could increase power by combining data from traits with overlapping influencing variants when accounting for the directional effects. In the Danish iPSYCH cohort, we assessed PRS-based predictions for developing recurrent depression and psychiatric comorbidity over time and found significant differences in hazard rates and absolute risks between MD cases in the highest and lowest PRS deciles. The iPSYCH cohort includes relatively young individuals (mean age 23.37 years, SE = 6.9, at follow-up December 31st 2016) and thus, a substantial number of the MD cases will develop recurrent MD and/or comorbid disorders later in life. This indicates that the observed risks, and likely also the differences across PRS deciles, will increase further over time. Moreover, the prediction could probably be improved by including other risk factors such as e.g. family history⁹⁰ and clinical/phenotypic variables, as it has been shown in other complex disorders⁹¹. In clinical settings, a targeted effort could be envisaged that offer intensified monitoring for development of e.g. BP, SZ or ANX among MD cases with the highest PRS burden (or

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

combined genetic and clinical risk) to obtain early diagnosis and initiate early treatment, which may have beneficial effects^{92,93}. Similarly, identifying high risk for developing SUD could potentially be an informative point of attention for both the physician and the patient⁹⁴. However, assessment of the clinical utility at the individual level of such potential applications is warranted⁹⁵. Methods Samples The iPSYCH2015 sample is a nation-wide population sample extracted from a baseline cohort consisting of all children born in Denmark between May 1, 1981, and December 31, 2008, who were alive and resided in Denmark on their one-year birthday, and who have a known mother^{24,25}. Individuals diagnosed with one (or more) of six major psychiatric disorders (ADHD, ASD, MDD, BP, SZ, Anorexia) were identified via the Danish Psychiatric Central Research Register²⁶, which includes data on all individuals treated in Denmark at psychiatric hospitals (from 1969 onward) as well as at outpatient psychiatric clinics (from 1995 onward). A random sample from the same birth cohort were chosen as control group. The iPSYCH2015 cohort consists of the initial case-cohort sample iPSYCH2012²⁵ and the recent extension iPSYCH2015i²⁴. Individuals with a ICD10 F32-F33 diagnosis in 2016 or earlier were considered as MD cases and the random population-based sample excluding individuals with an MD diagnosis were used as controls. All individuals diagnosed with BP were excluded, except for the analyses involving co-occurrence of MD and BP diagnosis. MD cases were divided into two groups; 1) individuals diagnosed with a single episode of depression, and 2) those fulfilling the criteria for recurrent depression. The date of the first depression episode for each individual

All rights reserved. No reuse allowed without permission.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

was defined as the start date of the first contact in the Danish Psychiatric Central Research Register with an ICD-10 code of F32-F33 diagnoses at an age of 10 years or older. When defining later depression episodes only contacts with the ICD-10 codes: F32, F33.0-F33.3, F33.8-F33.9 were considered. Individuals with the ICD-10 code F33.4 "Major depressive disorder, recurrent, in remission" were omitted because these contacts are unlikely to indicate a new episode of depression. Only ICD-10: F32, F33.0-F33.3, F33.8-F33.9 diagnosis at dates later than 60 days after the end date for all previous ICD10: F32-F33 diagnosis were considered as new episodes of depression, thus categorizing that particular individual as having recurrent depression. In addition to depression phenotypes, individuals with the following diagnoses were recorded in the iPSYCH sample: BP (F30-F31), SZ (F20), SUD (F10-F19, excluding F1X.0 acute intoxication), ANX (F40-F43), ASD (F84.0, F84.1, F84.5, F84.8 or F84), ADHD (F90.0). In the iPSYCH2015 cohort²⁴, we have added 11,710 MD cases and 18,410 controls to the iPSYCH2012 sample^{12,25}, summarizing to a total of 34,095 cases and 45,393 controls prior to relatedness pruning and removal of ancestry outliers (Supplementary Table S14). A total of 30,618 cases and 38,200 controls were retained after relatedness pruning and removal of ancestry outliers (Supplementary Table S14). Of these, 6,517 had recurrent episodes of depression (see definition in Methods), while 24,101 were classified as single-episode depression cases (Supplementary Table S14). The number of cases with an additional psychiatric diagnosis (BP, SZ, ANX, ASD, ADHD, SUD) are shown in Supplementary Table S17. Individuals with a diagnosis of BP were excluded from all subsequent analyses except for analyses involving BP. Whether recurrent depression was associated with increased comorbidity compared to single-

episode depression was tested using logistic regression for each additional diagnosis while

4

9

11

14

15

17

21

24

25

adjusting for age. Individuals were grouped in five-year age bins in order to construct dummy 2 variables for the age adjustment (Supplementary Table S17). 3 All analyses of the iPSYCH sample were performed at the secured national GenomeDK high-5 performance computing cluster in Denmark. The study was approved by the Scientific Ethics 6 Committee in the Central Denmark Region and the Danish Data Protection Agency. The study was 7 approved by the appropriate local scientific ethics committees and IRBs. 8 10 Genotyping, QC and imputation iPSYCH2015 samples were linked via the unique national personal identification number to 12 the Danish Neonatal Screening Biobank (DNSB) at Statens Serum Institute (SSI), where 13 DNA was extracted from Guthrie cards, and whole-genome amplification was performed in triplicate, as described previously^{96,97}. Genotyping in iPSYCH2012 was performed using the PsychArray V1.0 (Illumina, San 16 Diego, California), while genotyping of iPSYCH2015i was done using the Global Screening Array v2 (Illumina, San Diego, California). Since the two samples were genotyped on 18 different platforms, they were QCed and imputed separately. 19 Genotyping of the iPSYCH2012 sample was performed at the Broad Institute of Harvard and 20 MIT (Cambridge, MA, USA) with PsychChip arrays from Illumina according to the manufacturer's instructions. Genotype calling of markers with MAF > 0.01 was performed by merging call sets from GenCall⁹⁸ and Birdseed⁹⁹, and less frequent variants (MAF < 0.01) 22 23 were called with zCall¹⁰⁰. Genotyping and data processing were carried out in 23 waves. Genotyping of the iPSYCH2015i sample was performed at Statens Serum Institut (SSI, Copenhagen, Denmark) using the Global Screening Array v2 with a Multi disease drop in

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

(Illumina, San Diego, California) according to the manufacturer's instructions. Genotype calling of markers was performed using GenTrain V3. Preimputation quality control was performed using the Ricopili¹⁰¹ pipeline with the specified parameters in the following order. Initially SNPs with a call rate < 0.95 were removed, and subsequently all individuals with a call rate in cases or controls of < 0.95 or an autosomal heterozygosity deviation F_{HET} outside the interval [-0.2;0.2] were removed. Individuals where stated sex was not consistent with sex derived from genotypes were flagged. Subsequently QC was conducted at the marker level, keeping markers with call rate ≥ 0.98 , missing difference ≤ 0.02 between cases and controls, with MAF \geq 0.01, Hardy-Weinberg equilibrium (HWE) in controls p value \geq 1 x 10⁻⁰⁶ and Hardy-Weinberg equilibrium (HWE) in cases p value $\geq 1 \times 10^{-10}$ (See https://sites.google.com/a/broadinstitute.org/ricopili/preimputation-qc for further details). The effects of three batch variables on marker genotypes were tested in iPSYCH2012 (ArrayPlate.ID, PreProc.Plate and wave) and iPSYCH2015i separately (Array.Batch, ArrayPlate.ID and PreProc.Plate). This was done using relatedness-pruned dataset with ancestry outliers removed in order to avoid removal of markers where batch effects were caused by population structure or cryptic relatedness rather than genotype artefacts. Pairwise relatedness coefficients ($\hat{\pi}$) were estimated with plink using a LD pruned and MAF filtered set of SNPs (snps-only, window size = 5,000, step size = 300, $r^2 < 0.05$, MAF > 0.05). Principal Component Analysis was conducted using the same set of LD pruned and MAF filtered SNPs, with random removal of one member of each pair with a relatedness coefficient $(\hat{\pi})$ higher than 0.2. Eigenvectors were inferred using EIGENSOFT version 6.1.4 on the relatedness-pruned set of individuals, and subsequently projecting all individuals onto those eigenvectors based on their genotypes. Individuals with all four grandparents born in

Denmark were used as a reference for constructing a 3-dimensional ellipsoid using principal

1 components 1, 2 and 3 with a radius of 5 standard deviations from the mean. Individuals 2 located outside this ellipsoid were removed prior to the testing for batch effects. 3 Each genotyped marker was tested for association with each batch versus 4 the remaining batches pooled. This was done for the following batch-variables: 5 ArrayPlate.ID, PreProc.Plate and wave for iPSYCH2012 and Array.Batch, ArrayPlate.ID and 6 PreProc.Plate for iPSYCH2015i. Batch-association testing was conducted using plink 7 v1.90b4. 8 The exclusion of SNPs strongly associated with any of the batch-variables were based on 9 their minimum P-value across all associations per variable. The cut-off for the wave and Array.Batch was $min(p) < 2 \times 10^{-10}$ and for PreProc.Plate and ArrayPlate.ID $min(p) < 2 \times 10^{-10}$ 10 11 ¹², based on a Bonferroni correction for the number of markers tested and the number of 12 associations done per batch-variable trying to incorporate the degree of nestedness of these. 13 After removing SNPs falling for any of the above cut-off the remaining distribution was 14 evaluated using QQ-plots. The expected minimum p-distribution was calculated using the 15 inverse cumulative distribution of N independent distributions as suggested in supplementary of Schork et al. 102, N being the number batch-variable values. Reviewing these QQ-plots it is 16 17 evident that despite filtering by p-value some signal from the batch-variable remains in the dataset. 18 iPSYCH2012 and iPSYCH2015i were imputed using the ricopili pipeline¹⁰¹. Prephasing was 19 done using Eagle v2.3.5¹⁰³ and the subsequent imputation was conducted using Minimac3¹⁰⁴, 20 21 using the downloadable version of the Haplotype Reference Consortium (HRC) (accession number: EGAD00001002729)¹⁰⁵ as reference. 22

Relatedness pruning and removal of ancestry outliers

23

24

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Best guest genotypes from iPSYCH2012 and iPSYCH2015i were merged, filtered and LDpruned down to a set of roughly 30K markers, with imputation INFO score > 0.8, $r^2 < 0.075$, located outside regions of long-range LD as defined by Price et al. 106, minor allele frequency > 0.05 and no deviation from Hardy-Weinberg proportions (P > 1 x 10⁻⁴). Relatedness coefficients, based on "identity-by-state", were estimated using plink v1.9, in order to identify related (and duplicated samples), with $\hat{\pi} > 0.2$ and one individual of each such pair was subsequently excluded at random. PCA was carried out using the same set of filtered and LD-pruned SNPs as implemented in the ricopili pipeline¹⁰¹. A subsample of European ancestry was selected as an ellipsoid in the space of PC1-3 centred and scaled using the mean and 8 standard deviation of the subsample whose grandparents were all known to be born in Denmark. *FinnGen* The FinnGen (https://www.finngen.fi/en) study combines genotype data with longitudinal health register data of Finland, including the causes of death, inpatient, outpatient, and drug reimbursement registers. A GWAS for depression was conducted in FinnGen release 6 samples containing 28098 cases (ICD-10/9: F32 or F33) and 228817 controls without manic episodes (ICD10 F30), bipolar affective disorder (ICD-10: F31, ICD-9: 296[2-7], ICD8: 296), persistent mood disorders (ICD10: F34) or other or unspecified mood disorder (ICD10: F38,F39, ICD-8: 29699). Variants with an imputation info score < 0.6 were excluded. GWAS was run with SAIGE logistic mixed model (version 0.39.1) using age, sex, 10 PCs and genotyping batch as covariates. A GWAS for anxiety disorders was conducted in the FinnGen release 6 sample consisting of 7,671 cases with a generalized anxiety disorder (ICD-10: F41.1, ICD-9: 3000C, ICD-8:

9

11

12

13

14

15

17

21

24

25

300,00), panic disorder (ICD-10: F41.0; ICD-9: 3000B, 3002B) or phobic anxiety (ICD-10: 2 F40, ICD-9: 3002C, 3002D, 3002X) diagnoses and 161,438 controls without a history of any 3 psychiatric diagnoses (ICD-10: F00-F99, ICD-9: 290-319, ICD-8: 290-315). With ICD-9 4 codes the first three digits signify numerical value (e.g., the code 3002B is included in the 5 code range 290-319). Cases with psychotic disorders (ICD-10: F2; ICD-9: 295, 297, 298; ICD-8: 295, 297, 298), autism spectrum disorders (ICD-10: F84.0, F84.1, F84.5; ICD-9: 6 7 2990; ICD-8: 299,99) or intellectual disability (ICD-10: F7, ICD-9: 317-319; ICD-8: 311-8 315) were excluded. Additionally, the age range of controls was adjusted to match to that of cases. Subjects were genotyped with Illumina and Affymetrix arrays (Illumina Inc., San Diego, and 10 Thermo Fisher Scientific, Santa Clara, CA, USA) as described (https://www.finngen.fi/en/researchers/genotyping). Genotyping and imputation with the Finnish population-specific SISu v3 reference panel were conducted, as described (https://www.protocols.io/view/genotype-imputation-workflow-v3-0-xbgfijw). SNPs were pruned for minor allele frequency (MAF) > 0.01 and imputation info score > 0.8. GWAS was 16 performed using the Scalable and Accurate Implementation of GEneralized mixed model (SAIGE) v0.20¹⁰⁷ with a kinship matrix as a random effect and age, sex, the first 10 principal 18 components (PCs), and genotyping batch as fixed effects. 19 20 GWAS analyses Genome-wide-association analyses within iPSYCH were conducted using the RICOPILI 22 pipline¹⁰¹, applying an additive logistic regression model using dosages of the imputed 23 genotypes. Analyses were adjusted for PC 1-10 from a PCA using the remaining subsample after removal of ancestry outliers and pruning for relatedness. In addition, MD cases with a diagnosis of bipolar disorder were excluded.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Summary statistics from iPSYCH2015 and the following external samples were included in a fixed-effects variance-weighted meta-analysis in METAL²⁷: 1) 230,118 broadly defined MD cases and 545,339 controls from Howard et al. 2019¹⁴, including self-reported MD of 23andMe²² and the broadly defined MD phenotype of UKB; 2) 35,077 narrowly defined MD cases and 95,406 controls from Wray et al. 2018¹², excluding 23andMe²²; 3) depression phenotypes from the Million Veteran Program (MVP)²³ based on ICD codes derived from electronic health records (83,810 cases and 166,405 controls); 4) 28,098 cases with ICD-10 F32 and/or F33 diagnoses and 228,817 controls from FinnGen. For comparison, we also conducted a GWAS and several downstream analyses using a narrower definition of MD that excluded self-reported MD of 23andMe^{12,22} and the broadly defined MD phenotype of UKB^{14,21} (Supplementary Figure S5, Table S3). The results were very similar to the primary analyses without noteworthy differences. *SNP-heritability, genetic correlations and overlap with other phenotypes* We estimated SNP-heritability (h_{SNP}^2) for iPSYCH2015 cases with MD, single episode and recurrent depression and for the external GWAS summary statistics outlined above using LD score regression³⁵. Genetic correlations within iPSYCH and between iPSYCH and external GWAS summary statistics was estimated using LD score regression³⁵. In addition, the genetic correlations of MD meta-analysis, single-episode and recurrent depression with other phenotypes were, evaluated using LD score regression 108 at the LD Hub³⁶ website. We used all available phenotypes on LD Hub, but we performed analyses for the UKB traits (N = 597) and the remaining individual phenotypes (N = 258) separately. Levels of experiment-wide significance (Bonferroni correction for number of tests applied) were also established separately within the two groups, i.e. in the UKB traits (P < 8.38 x 10-5) and the remaining individual phenotypes (p < 0.00019), respectively. LD Hub traits were

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

supplemented with LD score regression³⁵ analyses performed locally using updated or inhouse GWAS summary statistics for traits not available at LD-hub. These include ADHD, ASD¹⁵, cannabis use disorder³⁷, cannabis use¹⁰⁹, alcohol dependence¹¹⁰, drinks per week, smoking ever¹¹¹, age of initiation as a regular smoker, current versus a former smoker (smoking cessation), number of cigarettes per day, smoking initiation ¹¹² We applied MiXeR⁴³ on our MD GWAS summary statistics and a selection of additional traits (Supplementary Table S7 and Figure 3) to estimate (i) the number of variants explaining 90% of the SNP heritability of each trait and (ii) the genetic overlap between MD and each trait. MiXeR analysis were conducted with default settings (https://github.com/precimed/mixer) in a two-step process: 1) a univariate model for each trait to produce estimates of the proportion of variants with non-zero additive genetic effect on the trait (i.e. "polygenicity") and the variance of effect sizes of these non-zero variants (i.e. "discoverability""). 2) the variance estimates obtained in the univariate analysis were applied in the bivariate model (i.e. MD vs. each of the additional traits) to obtain four estimates representing (i) zero-effect SNPs in both traits; (ii) SNPs with a specific non-zero effect on one of the two traits; and (iii) SNPs with a non-zero effect on both traits. Estimates of polygenic overlap and genetic correlation between pairs of traits were obtained by combining these four parameters. Conditional analysis and finemapping We identified potential independent genome-wide significant lead variants for each of the broadly defined genome-wide-significant locus identified pipeline from our GWAS metaanalysis results 101: Neighboring index SNPs were considered independent when $r^2 < 0.1$ in a sliding 3 Mb window. For each index SNP we defined the associated LD-region by recording the left and rightmost variant with $r^2 < 0.1$. To define GWAS loci, a 50kb window was added

1 on each side of the LD-region and overlapping LD-regions were combined into a single locus. 2 Only a single SNP was kept from within the MHC region, due to extended linkage 3 disequilibrium and a strong association signal of the MHC region (chr 6:25-35 Mb). 4 In order to identify additional independent index variants, we performed a stepwise model 5 selection procedure to select independently associated SNPs also implemented in GCTA-6 $COJO^{28,29}$. 7 We assigned posterior probabilities (PP) of being causal to SNPs and constructed credible 8 sets of SNPs that cumulatively capture 95% of the regional posterior probability¹¹³ using PAINTOR¹¹⁴⁻¹¹⁶, CAVIARBF and FINEMAP¹¹⁷, using the CUASALdb pipeline 10 (https://github.com/mulinlab/CAUSALdb-finemapping-pip). We applied a conservative approach and assumed one causal variant for each locus. 12 Co-localization analyses were performed in order to evaluate the extent of overlap between 13 eQTL and GWAS signatures in MD and to identify putative causal genes from GWAS 14 associations. Considering only the 95% credible SNPs from the fine-mapped MD-meta-15 analysis, we integrated GWAS results and eOTL data from a previous meta-analysis integrating signals among three brain datasets⁵⁷ applying a fixed-effect model. The eQTL 16 17 data originates from eQTL meta-analysis on RNA-sequenced gene expression data from the dorsolateral prefrontal cortex from PsychENCODE⁵⁴ and ROSMAP¹¹⁸, and from 13 brain 18 regions from GTEx¹¹⁹. 19 20 Using the Coloc method^{58,59}, we extraced eQTL signals of genes within 200 kb distance to significant GWAS variants (P < 5 x 10^{-8}) using effect sizes (β -values) and standard errors from eQTL and GWAS as input. Four hierarchical hypotheses⁵⁹ were tested: H0, no 22 23 association; H1, GWAS association only; H2, eQTL association only; H3, both GWAS and 24 eQTL association but no co-localization; H4, both GWAS and eQTL association and co-

9

11

21

25

localization, considering PPH4 > 0.8 as strong evidence from both GWAS, eQTL and co-

1 localization. In addition, we conducted the eQTL and GWAS CAusal Variants Identification

in Associated Regions (eCAVIAR) approach⁶⁰, in which, both eQTL and GWAS were fine-2

mapped, and the product of posterior probability (CLPP) was calculated, prioritizing genes

with at least a single variant with CLPP ≥ 0.01 .

Gene-wise and pathway analysis

3

4

5

6

8

11

12

13

16

17

18

19

20

21

22

23

24

25

7 We used a number of different approaches and data including those available via the FUMA

v1.3.6a⁵² website (http://fuma.ctglab.nl) for downstream annotation and functional

9 characterization of significant loci.

10 We performed a genome-wide gene-based association study using the Multi-Marker Analysis

of GenoMic Annotation (MAGMA) tool, as implemented in FUMA version 1.3.6a⁵². Using

this we mapped SNPs from the MD GWAS meta-analysis to 17,840 protein coding genes, and

performed Bonferroni correction for the total number of protein-coding genes ($P < 2.8 \times 10^{-6}$,

14 Supplementary Table S9D).

15 Protein coding genes were mapped if they were located with a distance of 10Kb up- or

downstream index variants or if a credible variant was annotated to the gene based on eQTL

data or chromatin interaction data from human brain (data sets used in the mapping can be

found in the Supplementary Note). No additional variant filtering by functional annotation was

applied in the eQTL and chromatin interaction mapping. This analysis identified 411 MD risk

genes, which were used in a gene-set enrichment analysis within the GENE2FUNC module of

FUMA, where we analyzed 8,664 gene-sets derived from GO Biological Process (N = 7.658):

393 gene-sets) and GO Cellular Components (N = 1,006; 86 gene-sets) ontology in the

MSigDB database.

Tissue and cell type enrichment

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

We also used FUMA to perform tissue expression analyses on data available through their website, by tested whether the identified genetic associations for both the primary and narrow MD phenotype definitions were enriched regarding transcriptome profiles of human tissues using summary statistics based on all SNPs. Finally, we used FUMA to perform cell-type enrichment analyses⁵² based the MD GWAS summary statistics. We use MAGMA geneproperty analysis to test cell type specificity of phenotype with GWAS summary statistics. MAGMA gene-property analysis with scRNA-seq: The gene-property analysis aims to test relationships between cell specific gene expression profiles and disease-gene associations. In all above-mentioned analyses implemented in FUMA default settings were applied. To further evaluate whether the genomic loci implicated in MD are enriched in any particular cell type, we intersected common MD risk variants with two recent epigenomic maps of cellspecific open chromatin^{61,62} using LD score partitioned heritability approach⁶³(Supplementary Figure S14). *Transcriptome-wide association study* In addition, we performed a transcriptome-wide association study (TWAS), imputing the genetically regulated gene expression using EpiXcan⁵³ and using models trained on PsychENCODE Consortium (PEC)^{54,55} expression data for genes and transcripts detected in the dorsolateral prefrontal cortex (DLPFC), with the aim of identifying and prioritizing putative causal loci for the broad MD phenotype definition. A total of 34,646 genes/transcripts were tested (transcripts with prediction performance $R^2 > 0.01$ and prediction performance q value < 0.05 with the Benjamini-Hochberg method were retained), and applying a significance threshold of P < 1.44 x 10⁻⁶ (corresponding to Bonferroni correction of all genes and isoforms tested; Figure 1A, S9 and Table S11), using information on approximately independent linkage disequilibrium blocks in human populations⁵⁶ to

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

identify independent genomic regions with genes/transcripts showing significant differential gene expression between MD cases and controls. Polygenic risk scores Using available summary statistics form published GWAS as training datasets, we calculated polygenic risk scores (PRS) for individuals in the iPSYCH2015 sample using LDpred2¹²⁰. Summary statistics were filtered for an imputation info score INFO \geq 0.9 if available. When using external summary stats not processed using RICOPILI or imputed using different imputation references, we excluded all ambiguous markers to avoid potential strand conflicts. To improve performance of the scores and avoid including artefacts from batch effects, we restricted the summary stats to include only SNPs known to be present in both the iPSYCH2012 and iPSYCH2015i data at a reasonable quality (info score 0.6 and MAF 0.01). This step also checked for allele flips. To derive a PRS for MD within the iPSYCH2015 sample we used the MD meta-analysis 12,14,22,23 excluding all iPSYCH samples as training. We also calculated PRS based on GWAS summary statistics from BP¹²¹, SZ¹²², ADHD¹³ and ASD¹⁵. The PRSs for ADHD and ASD were based on a combination of external GWAS sumstats and internal training. A meta-analysis of two GWAS for anxiety, one based on self-report of physician diagnosis of ANX in the MVP¹²³ and the other being core anxiety in the FinnGen cohort (see FinnGen description above), served as weights for generating an ANX-PRS summarizing genetic risk of anxiety. To derive a PRS for neuroticism we used GWAS summary stats of a weighted neuroticism sum-score, constructed by adding up ten individual item responses (Fed-up, Guilt, Irr, Miss, Mood, Tense, Nerv feel, Suf Nerv, worry emb and worry) by Nagel et al.¹²⁴. In addition, we calculated PRSs using the following GWAS summary stats for traits related to substance-use and substance-use-disorder as training datasets. These include cannabis use disorder³⁷ (excluding iPSYCH samples, i.e., training only based on data from PGC and

data from decode genetics), cannabis use¹⁰⁹, alcohol dependence¹¹⁰, drinks per week, smoking

1 ever¹¹¹, age of initiation as a regular smoker, current versus a former smoker (smoking cessation),

2 number of cigarettes per day, smoking initiation¹¹². All summary statistics were combined in a

pseudo-meta-analysis, subsequently used for generating a SU-PRS summarizing genetic liability for

substance use while summary stats for alcohol dependence¹¹⁰ and cannabis use disorder³⁷ were

pseudo-meta-analyzed to generate a SUD-PRS summarizing genetic liability of substance use

6 disorder.

3

4

5

7

9

10

12

13

14

19

20

22

23

24

8 With the aim at improving the PRS prediction we attempted to exploit the genetic overlap of MD

with other phenotypes. We therefore combined all of the above PRSs into a single score as a

weighted sum¹⁵. We chose here to use the log(OR) for the logistic regression of sub-phenotype of

interest on each score as a continuous factor as a measure of 'importance' in context of the sub-

phenotype of interest (either recurrent vs. single-episode or MD with additional diagnosis of BP, SZ

or SUD) and adjusting for PCs. We added a PRS weighted by its log(OR) and the standardized one

PRS at the time, starting with the phenotype with highest abs(log(OR)) and ending with the lowest.

15 This way we ended up with a sequence of scores

starting with S_0 and continuing with:

17
$$S_{k} = \frac{\sum_{i=1}^{k} \log(OR_{P_{i}}) S_{P_{i}} - \mu(\sum_{i=1}^{k} \log(OR_{P_{i}}) S_{P_{i}})}{\sigma(\sum_{i=1}^{k} \log(OR_{P_{i}}) S_{P_{i}})}$$

Where S_{P_i} is the score for phenotype P_i , OR_{P_i} the odds ratio from the logistic regression of sub-

phenotype of interest on S_{Pi} as a continuous factor adjusting for PCs, and μ is the mean and σ the

standard deviation.

21 To examine potential polygenic heterogeneity across MD sub-phenotypes, we investigated how PRS

trained on the different phenotypes described above were distributed across MD sub-phenotypes in

iPSYCH using a multivariate PRS approach. The method is described in detail in Grove et al. 15, and

is a regression of multiple outcome variables, and in principle a linear regression for each PRS on the

4

8

9

10

11

12

13

14

15

17

18

21

22

23

24

25

MD sub-phenotypes allowing for comparisons on the average PRS across sub-phenotypes for PRS 2 from a number of phenotypes while accounting for the inherent correlation between scores and 3 adjusting for necessary covariates. MD-BP cases were excluded from the analyses not involving BP. In addition, we applied a Cox proportional hazard model to estimate hazard rate ratios and absolute 5 risk of developing 1) a second episode of MD, 2) BP, 3) SZ and 4) SUD, among individuals already being diagnosed with their first episode of MD. Analyses were stratified by PRS deciles of the 6 7 phenotypes described above and using functions from the R-packages survival (https://CRAN.Rproject.org/package=survival)^{125,126} and survminer (https://CRAN.Rproject.org/package=survminer), while correcting for batch (iPSYCH2012 and iPSYCH2015i) and PCs using an in-house pipeline. MD-PRS in the Philadelphia Neurodevelopmental Cohort (PNC) MD-PRS were calculated for 4,973 individuals of European ancestry from the Philadelphia Neurodevelopmental Cohort (PNC)^{45,46} using the primary MD GWAS meta-analysis of the current study as training. Genotypes from the first PNC release (dbGaP phs000607.v1.p1) and 16 neurocognitive phenotypes from the third release (dbGaP phs000607.v3.p2) were utilized. Individuals whose genotypically inferred and phenotypically reported sex did not match, those who did not meet the identity by descent (IBD) filter ($\hat{\pi} > 0.185$), those who did not meet the individuallevel missingness filter of 0.05, and those with heterozygosity rates +/- three standard deviations 19 20 from the mean were removed. SNPs that failed to meet the Hardy-Weinberg proportions (HWP), minor allele frequency (MAF), and SNP-level missingness filters of 0.00001, 0.01, and 0.05, respectively, were also removed. Genotype imputation was performed using the reference panel HRC r1.1 2016 on the Michigan Imputation Server (https://imputationserver.sph.umich.edu/index.html#!), selecting the "Mixed population" option. Imputed SNPs with an imputation R^2 of < 0.03 and those who failed to meet the missingness, MAF,

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

and HWP thresholds stated above were removed. The first two Multi-Dimensional Scaling (MDS) dimensions were plotted to identify and remove outlier genotypes. The GemTools package in R (http://www.compgen.pitt.edu/GemTools/GEM%20Documentation.pdf) and Ward's hierarchical clustering methods were used to identify individuals of European ancestry. PRS-CS¹²⁷ was used to assign per-allele posterior SNP effect sizes to MD GWAS summary statistics. A European LD reference panel provided by the developers of PRS-CS was utilized (https://github.com/getian107/PRScs), which draws from the 1000 Genomes Project data. The following PRS-CS default settings were used: parameter a in the γ - γ prior = 1, parameter b in the γ - γ prior = 0.5, MCMC iterations = 1,000, number of burn-in iterations = 500, and thinning of the Markov chain factor = 5. The global shrinkage parameter phi was set using a fully Bayesian determination method. Individual-level MD-PRS were calculated using Plink v2.0¹²⁸. The associations between scaled (mean = 0, SD = 1) MD-PRS and 15 scaled neurocognitive phenotypes in the PNC were assessed using linear regression. Covariates included in the analysis were age at neurocognitive testing, age squared, the first 10 MDS dimensions, sex, and genotyping batch. Adjusted R² was used to report the total variance explained by MD-PRS and model covariates for the 15 tested neurocognitive phenotypes. Additionally, a variance partitioning tool (https://github.com/GabrielHoffman/misc_vp/blob/master/calcVarPart.R) was used to determine the variance explained by MD-PRS and each covariate individually. FDR-adjusted p-values were reported. Data availability Summary statistics from this publication are available at http://ipsych.au.dk/downloads/. All relevant iPSYCH data are available from the authors after approval by the iPSYCH Data

Access Committee and can only be accessed on the secured Danish server (GenomeDK,

All rights reserved. No reuse allowed without permission.

1 https://genome.au.dk) as the data are protected by Danish legislation. For data access please 2 contact: Anders D. Børglum. 3 Data used for brain transcriptome model generation are available from PsychENCODE 4 (overview of available data sets at http://resource.psychencode.org/); genotypes are 5 controlled data and access instructions are provided at 6 https://www.synapse.org/#!Synapse:syn4921369/wiki/477467. Note that some datasets have 7 been indirectly accessed at the respective analytical websites (through the FUMA website). 8 Please refer to these websites (e.g., for FUMA https://fuma.ctglab.nl/links and 9 https://fuma.ctglab.nl/tutorial#datasets) for availability of datasets used in the respective 10 follow-up analyses / lookups. 11 12 **Code availability** 13 Please refer to individual sections of the methods above for published code (e.g., Ricopili, 14 LDpred2, MiXeR). Because the in-house scripts used for data processing and analysis of the 15 iPSYCH data on the GenomeDK HPC infrastructure is highly dependent on that context, they 16 can only be obtained from the authors upon request. This way we can ensure the proper 17 context is explained in dialogue with the interested parties. 18 19 **Inclusion and ethics** 20 The research has included local researchers throughout the research process, including study design, 21 study implementation, data ownership, intellectual property and authorship of publications. Roles 22 and responsibilities were agreed amongst collaborators ahead of the research. 23 This research does not result in stigmatization, incrimination, discrimination or any personal risk of 24 the participants. Local and regional research relevant to the study have been considered in the listed

25

citations.

Acknowledgements

1

- 2 The iPSYCH team was supported by grants from the Lundbeck Foundation (R102-A9118, R155-
- 3 2014-1724, and R248-2017-2003), the EU H2020 Program (Grant No. 667302, "CoCA"),
- 4 NIH/NIMH (1U01MH109514-01 and 1R01MH124851-01 to ADB) and the Universities and
- 5 University Hospitals of Aarhus and Copenhagen. The Danish National Biobank resource was
- 6 supported by the Novo Nordisk Foundation. High-performance computer capacity for handling and
- 7 statistical analysis of iPSYCH data on the GenomeDK HPC facility was provided by the Center for
- 8 Genomics and Personalized Medicine and the Centre for Integrative Sequencing, iSEQ, Aarhus
- 9 University, Denmark (grant to ADB).
- We would like to thank the research participants and employees of 23andMe, Inc. for making this
- 11 work possible.

15

25

- 12 The team at the Center for Disease Neurogenomics at Icahn School of Medicine at Mount Sinai was
- 13 supported by the NIH (K08MH122911 to GV; T32MH087004 to KT; R01MH125246,
- 14 R01AG067025, U01MH116442 and R01MH109677 to PR).
- 16 **Author contributions**
- Analysis: TDA, MK, JG, GV, KT, ET, TTN, JN, KV, DL, JB, and BZ
- 18 Sample and/or data provider and processing: J.B.Grauholm, D.D., A.R., G.A., M.B.Hansen, P.Q.,
- 19 B.W., T.T., H.S., K.L.M., V.M., L.F., J.T., B.J.V., J.J.M., M.M, S.M., iPSYCH-Broad Consortium,
- 20 E.A., K.S., M.M., T.W., D.M.H., P.B.M., M.S., J.G., I.H., P.R., M.J.D., O.M., A.P., and A.D.B.
- 21 **Supervision:** P.Q., K.L.M., B.J.V., J.J.M, I.H., P.R., M.J.D., O.M., A.P., and A.D.B.
- Writing: T.D.A. and A.D.B.
- 23 Study design and direction: A.D.B.
- 24 All authors contributed with critical revision of the manuscript.

All rights reserved. No reuse allowed without permission.

Competing interests

1

6

8

- 2 B.J.V. is a member of the advisory board for Allelica. D.D. has received a speaker fee from Takeda.
- 3 B.W., T.T., H.S. and K.S. are employed at deCODE/Amgen. M.J.D. is a founder of Maze
- 4 Therapeutics and on the Scientific Advisory Board of RBNC Therapeutics. The other authors declare
- 5 no competing interests.

7 References

- 9 1 Kessler, R. C. & Bromet, E. J. The epidemiology of depression across cultures. *Annual review of public health* **34**, 119-138, doi:10.1146/annurev-publhealth-031912-114409 (2013).
- Hasin, D. S. *et al.* Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. *JAMA psychiatry* **75**, 336-346, doi:10.1001/jamapsychiatry.2017.4602 (2018).
- Pedersen, C. B. *et al.* A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders. *JAMA psychiatry* **71**, 573-581, doi:10.1001/jamapsychiatry.2014.16 (2014).
- Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T. & Murray, C. J. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. *Lancet* **367**, 1747-1757, doi:10.1016/S0140-6736(06)68770-9 (2006).
- Wittchen, H. U. *et al.* The size and burden of mental disorders and other disorders of the brain in Europe 2010. *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* **21**, 655-679, doi:10.1016/j.euroneuro.2011.07.018 (2011).
- Gustavsson, A. *et al.* Cost of disorders of the brain in Europe 2010. *European*neuropsychopharmacology: the journal of the European College of
 Neuropsychopharmacology **21**, 718-779, doi:10.1016/j.euroneuro.2011.08.008
 (2011).
- Angst, F., Stassen, H. H., Clayton, P. J. & Angst, J. Mortality of patients with mood disorders: follow-up over 34-38 years. *J Affect Disord* **68**, 167-181 (2002).
- Ferrari, A. J. *et al.* Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. *PLoS medicine* **10**, e1001547, doi:10.1371/journal.pmed.1001547 (2013).
- 9 Plana-Ripoll, O. *et al.* Exploring Comorbidity Within Mental Disorders Among a Danish National Population. *JAMA psychiatry* **76**, 259-270, doi:10.1001/jamapsychiatry.2018.3658 (2019).
- Steffen, A., Nubel, J., Jacobi, F., Batzing, J. & Holstiege, J. Mental and somatic comorbidity of depression: a comprehensive cross-sectional analysis of 202 diagnosis groups using German nationwide ambulatory claims data. *BMC Psychiatry* **20**, 142,
- 40 doi:10.1186/s12888-020-02546-8 (2020).

- Sullivan, P. F., Neale, M. C. & Kendler, K. S. Genetic epidemiology of major depression: review and meta-analysis. *Am J Psychiatry* **157**, 1552-1562, doi:10.1176/appi.ajp.157.10.1552 (2000).
- Wray, N. R. *et al.* Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *Nat Genet* **50**, 668-681, doi:10.1038/s41588-018-0090-3 (2018).
- Demontis, D. *et al.* Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. *Nature Genetics*, doi:10.1038/s41588-018-0269-7 (2018).
- Howard, D. M. *et al.* Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions.

 Nat Neurosci 22, 343-352, doi:10.1038/s41593-018-0326-7 (2019).
- 13 Grove, J. *et al.* Identification of common genetic risk variants for autism spectrum disorder. *Nat Genet* **51**, 431-444, doi:10.1038/s41588-019-0344-8 (2019).
- 15 Quello, S. B., Brady, K. T. & Sonne, S. C. Mood disorders and substance use disorder: a complex comorbidity. *Sci Pract Perspect* **3**, 13-21, doi:10.1151/spp053113 (2005).
- Davis, L., Uezato, A., Newell, J. M. & Frazier, E. Major depression and comorbid substance use disorders. *Curr Opin Psychiatry* **21**, 14-18, doi:10.1097/YCO.0b013e3282f32408 (2008).
- Murray, G. K. *et al.* Could Polygenic Risk Scores Be Useful in Psychiatry?: A Review. JAMA psychiatry **78**, 210-219, doi:10.1001/jamapsychiatry.2020.3042 (2021).
- Rees, E. & Owen, M. J. Translating insights from neuropsychiatric genetics and genomics for precision psychiatry. *Genome Med* **12**, 43, doi:10.1186/s13073-020-00734-5 (2020).
- Perkins, D. O. *et al.* Polygenic Risk Score Contribution to Psychosis Prediction in a
 Target Population of Persons at Clinical High Risk. *Am J Psychiatry* 177, 155-163,
 doi:10.1176/appi.ajp.2019.18060721 (2020).
- Howard, D. M. *et al.* Genome-wide association study of depression phenotypes in UK Biobank identifies variants in excitatory synaptic pathways. *Nature communications* **9**, 1470, doi:10.1038/s41467-018-03819-3 (2018).
- Hyde, C. L. *et al.* Identification of 15 genetic loci associated with risk of major depression in individuals of European descent. *Nat Genet* **48**, 1031-1036, doi:10.1038/ng.3623 (2016).
- Levey, D. F. *et al.* Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. *Nat Neurosci* **24**, 954-963, doi:10.1038/s41593-021-00860-2 (2021).
- 37 24 Bybjerg-Grauholm, J. *et al.* The iPSYCH2015 Case-Cohort sample: updated directions for unravelling genetic and environmental architectures of severe mental disorders.
 39 *medRxiv*, 2020.2011.2030.20237768, doi:10.1101/2020.11.30.20237768 (2020).
- Pedersen, C. B. *et al.* The iPSYCH2012 case-cohort sample: new directions for unravelling genetic and environmental architectures of severe mental disorders. *Mol Psychiatry*, doi:10.1038/mp.2017.196 (2017).
- 43 26 Mors, O., Perto, G. P. & Mortensen, P. B. The Danish Psychiatric Central Research 44 Register. *Scand J Public Health* **39**, 54-57, doi:10.1177/1403494810395825 (2011).
- Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190-2191,
- 47 doi:10.1093/bioinformatics/btq340 (2010).

1	28	Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide
2		complex trait analysis. Am J Hum Genet 88, 76-82, doi:10.1016/j.ajhg.2010.11.011
3		(2011).

- Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. Genome-wide complex trait analysis (GCTA): methods, data analyses, and interpretations. *Methods in molecular biology* **1019**, 215-236, doi:10.1007/978-1-62703-447-0 9 (2013).
- Stankiewicz, P. *et al.* Haploinsufficiency of the Chromatin Remodeler BPTF Causes
 Syndromic Developmental and Speech Delay, Postnatal Microcephaly, and
 Dysmorphic Features. *Am J Hum Genet* **101**, 503-515,
 doi:10.1016/j.ajhg.2017.08.014 (2017).
- Ansar, M. *et al.* Biallelic variants in LINGO1 are associated with autosomal recessive intellectual disability, microcephaly, speech and motor delay. *Genetics in medicine : official journal of the American College of Medical Genetics* **20**, 778-784, doi:10.1038/gim.2017.113 (2018).
- de Ligt, J. *et al.* Diagnostic exome sequencing in persons with severe intellectual disability. *N Engl J Med* **367**, 1921-1929, doi:10.1056/NEJMoa1206524 (2012).
- Duman, R. S., Shinohara, R., Fogaca, M. V. & Hare, B. Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function. *Mol Psychiatry* **24**, 1816-1832, doi:10.1038/s41380-019-0400-x (2019).
- 34 Hara, H. *et al.* TAK-653, an AMPA receptor potentiator with minimal agonistic
 activity, produces an antidepressant-like effect with a favorable safety profile in rats.
 Pharmacol Biochem Behav 211, 173289, doi:10.1016/j.pbb.2021.173289 (2021).
- Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet* **47**, 291-295, doi:10.1038/ng.3211 (2015).
- Zheng, J. *et al.* LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. *Bioinformatics* **33**, 272-279, doi:10.1093/bioinformatics/btw613 (2017).
- Johnson, E. C. *et al.* A large-scale genome-wide association study meta-analysis of cannabis use disorder. *Lancet Psychiatry* **7**, 1032-1045, doi:10.1016/S2215-0366(20)30339-4 (2020).
- 33 38 Zhou, H. *et al.* Genome-wide meta-analysis of problematic alcohol use in 435,563 individuals yields insights into biology and relationships with other traits. *Nat Neurosci* **23**, 809-818, doi:10.1038/s41593-020-0643-5 (2020).
- 36 39 Deak, J. D. & Johnson, E. C. Genetics of substance use disorders: a review. *Psychol Med*, 1-12, doi:10.1017/S0033291721000969 (2021).
- 38 40 Gelernter, J. & Polimanti, R. Genetics of substance use disorders in the era of big data. *Nat Rev Genet*, doi:10.1038/s41576-021-00377-1 (2021).
- 40 41 Olvera, R. L. *et al.* Common genetic influences on depression, alcohol, and substance use disorders in Mexican-American families. *American journal of medical genetics*.

 42 Part B. Neuropsychiatric genetics: the official publication of the International Society.
- 42 Part B, Neuropsychiatric genetics: the official publication of the International Society 43 of Psychiatric Genetics **156B**, 561-568, doi:10.1002/ajmg.b.31196 (2011).
- 44 42 Adams, M. J. *et al.* Genetic stratification of depression by neuroticism: revisiting a diagnostic tradition. *Psychol Med* **50**, 2526-2535, doi:10.1017/S0033291719002629 (2020).

1	43	Frei, O. et al. Bivariate causal mixture model quantifies polygenic overlap between
2		complex traits beyond genetic correlation. Nature communications 10, 2417,
3		doi:10.1038/s41467-019-10310-0 (2019).

- 4 44 Demontis, D. *et al.* Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains. *medRxiv*, 2022.2002.2014.22270780, doi:10.1101/2022.02.14.22270780 (2022).
- Satterthwaite, T. D. *et al.* Neuroimaging of the Philadelphia neurodevelopmental cohort. *Neuroimage* **86**, 544-553, doi:10.1016/j.neuroimage.2013.07.064 (2014).
- Calkins, M. E. *et al.* The Philadelphia Neurodevelopmental Cohort: constructing a deep phenotyping collaborative. *J Child Psychol Psychiatry* **56**, 1356-1369, doi:10.1111/jcpp.12416 (2015).
- 12 47 Gur, R. C. *et al.* Age group and sex differences in performance on a computerized neurocognitive battery in children age 8-21. *Neuropsychology* **26**, 251-265, doi:10.1037/a0026712 (2012).
- Wilkinson, G. S. & Robertson, G. J. *Wide range achievement test (WRAT4)*. (Pearson).
- Cullen, B. *et al.* Cognitive function and lifetime features of depression and bipolar disorder in a large population sample: Cross-sectional study of 143,828 UK Biobank participants. *Eur Psychiatry* **30**, 950-958, doi:10.1016/j.eurpsy.2015.08.006 (2015).
- Lim, J. et al. Sensitivity of cognitive tests in four cognitive domains in discriminating
 MDD patients from healthy controls: a meta-analysis. *Int Psychogeriatr* 25, 1543 1557, doi:10.1017/S1041610213000689 (2013).
- Snyder, H. R. Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review.

 Psychol Bull 139, 81-132, doi:10.1037/a0028727 (2013).
- Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nature communications* **8**, 1826, doi:10.1038/s41467-017-01261-5 (2017).
- Zhang, W. *et al.* Integrative transcriptome imputation reveals tissue-specific and shared biological mechanisms mediating susceptibility to complex traits. *Nature communications* **10**, 3834, doi:10.1038/s41467-019-11874-7 (2019).
- Wang, D. *et al.* Comprehensive functional genomic resource and integrative model for the human brain. *Science* **362**, doi:10.1126/science.aat8464 (2018).
- Gandal, M. J. *et al.* Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. *Science* **362**, doi:10.1126/science.aat8127 (2018).
- Berisa, T. & Pickrell, J. K. Approximately independent linkage disequilibrium blocks in human populations. *Bioinformatics* **32**, 283-285, doi:10.1093/bioinformatics/btv546 (2016).
- Zeng, B. *et al.* Trans-ethnic eQTL meta-analysis of human brain reveals regulatory
 architecture and candidate causal variants for brain-related traits. *medRxiv*,
 2021.2001.2025.21250099, doi:10.1101/2021.01.25.21250099 (2021).
- Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *Plos Genet* **10**, e1004383,
- 45 doi:10.1371/journal.pgen.1004383 (2014).

1	59	Dobbyn, A. et al. Landscape of Conditional eQTL in Dorsolateral Prefrontal Cortex
2		and Co-localization with Schizophrenia GWAS. Am J Hum Genet 102, 1169-1184,
3		doi:10.1016/j.ajhg.2018.04.011 (2018).

- 4 60 Hormozdiari, F. et al. Colocalization of GWAS and eQTL Signals Detects Target Genes. 5 Am J Hum Genet **99**, 1245-1260, doi:10.1016/j.ajhg.2016.10.003 (2016).
- 6 Meuleman, W. et al. Index and biological spectrum of human DNase I hypersensitive 61 7 sites. Nature 584, 244-251, doi:10.1038/s41586-020-2559-3 (2020).
- 8 Corces, M. R. et al. Single-cell epigenomic analyses implicate candidate causal 62 9 variants at inherited risk loci for Alzheimer's and Parkinson's diseases. Nat Genet 52, 10 1158-1168, doi:10.1038/s41588-020-00721-x (2020).
- 11 63 Finucane, H. K. et al. Partitioning heritability by functional annotation using genome-12 wide association summary statistics. Nat Genet 47, 1228-1235, doi:10.1038/ng.3404 13 (2015).
- 14 64 Holmes, S. E. et al. Lower synaptic density is associated with depression severity and 15 network alterations. Nature communications 10, 1529, doi:10.1038/s41467-019-16 09562-7 (2019).
- 17 65 Wang, Y. T. et al. Novel rapid-acting glutamatergic modulators: Targeting the 18 synaptic plasticity in depression. Pharmacol Res 171, 105761, 19 doi:10.1016/j.phrs.2021.105761 (2021).
- 20 Szebeni, A. et al. Shortened telomere length in white matter oligodendrocytes in 66 21 major depression: potential role of oxidative stress. Int J Neuropsychopharmacol 17, 22 1579-1589, doi:10.1017/S1461145714000698 (2014).
- 23 Zhou, B., Zhu, Z., Ransom, B. R. & Tong, X. Oligodendrocyte lineage cells and 67 24 depression. Mol Psychiatry 26, 103-117, doi:10.1038/s41380-020-00930-0 (2021).
- 25 68 Leng, L. et al. Menin Deficiency Leads to Depressive-like Behaviors in Mice by 26 Modulating Astrocyte-Mediated Neuroinflammation. Neuron 100, 551-563 e557, 27 doi:10.1016/j.neuron.2018.08.031 (2018).
- 28 69 Musliner, K. L. et al. Polygenic liability, stressful life events and risk for secondary-29 treated depression in early life: a nationwide register-based case-cohort study. 30 Psychol Med, 1-10, doi:10.1017/S0033291721001410 (2021).
- 31 Musliner, K. L. et al. Polygenic Liability and Recurrence of Depression in Patients 70 32 With First-Onset Depression Treated in Hospital-Based Settings. JAMA psychiatry, 33 doi:10.1001/jamapsychiatry.2021.0701 (2021).
- 34 71 Richards, D. Prevalence and clinical course of depression: a review. Clin Psychol Rev 35 **31**, 1117-1125, doi:10.1016/j.cpr.2011.07.004 (2011).
- 36 72 Etchecopar-Etchart, D. et al. Comorbid Major Depressive Disorder in Schizophrenia: 37 A Systematic Review and Meta-Analysis. Schizophr Bull 47, 298-308,
- 38 doi:10.1093/schbul/sbaa153 (2021).
- 39 Green, E. K. et al. Variation at the GABAA receptor gene, Rho 1 (GABRR1) associated 73 40 with susceptibility to bipolar schizoaffective disorder. American journal of medical 41 genetics. Part B, Neuropsychiatric genetics: the official publication of the 42 International Society of Psychiatric Genetics 153B, 1347-1349, 43 doi:10.1002/ajmg.b.31108 (2010).
- 44 74 Gulsuner, S. et al. Genetics of schizophrenia in the South African Xhosa. Science 367, 45 569-573, doi:10.1126/science.aay8833 (2020).
- 46 75 Brennand, K. J. et al. Modelling schizophrenia using human induced pluripotent stem 47 cells. Nature 473, 221-225, doi:10.1038/nature09915 (2011).

1	76	Duman, R. S., Sanacora, G. & Krystal, J. H. Altered Connectivity in Depression: GABA
2		and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments. Neuron
3		102 75-90 doi:10.1016/i.neuron.2019.03.013.(2019)

- Selten, M., van Bokhoven, H. & Nadif Kasri, N. Inhibitory control of the excitatory/inhibitory balance in psychiatric disorders. *F1000Res* **7**, 23, doi:10.12688/f1000research.12155.1 (2018).
- 7 78 Gao, R. & Penzes, P. Common mechanisms of excitatory and inhibitory imbalance in schizophrenia and autism spectrum disorders. *Curr Mol Med* **15**, 146-167, doi:10.2174/1566524015666150303003028 (2015).
- Bruining, H. *et al.* Measurement of excitation-inhibition ratio in autism spectrum disorder using critical brain dynamics. *Scientific reports* **10**, 9195, doi:10.1038/s41598-020-65500-4 (2020).
- Nelson, S. B. & Valakh, V. Excitatory/Inhibitory Balance and Circuit Homeostasis in Autism Spectrum Disorders. *Neuron* **87**, 684-698, doi:10.1016/j.neuron.2015.07.033 (2015).
- Sequeira, A. *et al.* Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. *PLoS One* **4**, e6585, doi:10.1371/journal.pone.0006585 (2009).
- Merali, Z. *et al.* Dysregulation in the suicide brain: mRNA expression of corticotropinreleasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. *J Neurosci* **24**, 1478-1485, doi:10.1523/JNEUROSCI.4734-03.2004 (2004).
- Vinkers, C. H., Mirza, N. R., Olivier, B. & Kahn, R. S. The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipeline. *Expert Opin Investig Drugs* **19**, 1217-1233, doi:10.1517/13543784.2010.513382 (2010).
- 26 84 Engin, E., Liu, J. & Rudolph, U. alpha2-containing GABA(A) receptors: a target for the development of novel treatment strategies for CNS disorders. *Pharmacol Ther* **136**, 142-152, doi:10.1016/j.pharmthera.2012.08.006 (2012).
- 85 Braat, S. & Kooy, R. F. The GABAA Receptor as a Therapeutic Target for
 30 Neurodevelopmental Disorders. *Neuron* 86, 1119-1130,
 31 doi:10.1016/j.neuron.2015.03.042 (2015).
- Duncan, C. E. *et al.* Prefrontal GABA(A) receptor alpha-subunit expression in normal postnatal human development and schizophrenia. *J Psychiatr Res* **44**, 673-681, doi:10.1016/j.jpsychires.2009.12.007 (2010).
- Benasi, G. *et al.* Benzodiazepines as a Monotherapy in Depressive Disorders: A Systematic Review. *Psychother Psychosom* **87**, 65-74, doi:10.1159/000486696 (2018).
- Fasipe, O. J., Agede, O. A. & Enikuomehin, A. C. Announcing the novel class of GABA-A receptor selective positive allosteric modulator antidepressants. *Future Sci OA* **7**, FSO654, doi:10.2144/fsoa-2020-0108 (2020).
- ten Doesschate, F. *et al.* Neural excitation/inhibition imbalance and the treatment of severe depression. *bioRxiv*, 2021.2007.2009.451784, doi:10.1101/2021.07.09.451784 (2021).
- Hujoel, M. L. A., Loh, P.-R., Neale, B. M. & Price, A. L. Incorporating family history of disease improves polygenic risk scores in diverse populations. *bioRxiv*,
- 46 2021.2004.2015.439975, doi:10.1101/2021.04.15.439975 (2021).

- Torkamani, A., Wineinger, N. E. & Topol, E. J. The personal and clinical utility of polygenic risk scores. *Nat Rev Genet* **19**, 581-590, doi:10.1038/s41576-018-0018-x (2018).
- Vieta, E. *et al.* Early Intervention in Bipolar Disorder. *Am J Psychiatry* **175**, 411-426,
 doi:10.1176/appi.ajp.2017.17090972 (2018).
- Lieberman, J. A., Small, S. A. & Girgis, R. R. Early Detection and Preventive
 Intervention in Schizophrenia: From Fantasy to Reality. *Am J Psychiatry* 176, 794-810, doi:10.1176/appi.ajp.2019.19080865 (2019).
- 9 94 Carney, T. & Myers, B. Effectiveness of early interventions for substance-using adolescents: findings from a systematic review and meta-analysis. *Subst Abuse Treat Prev Policy* **7**, 25, doi:10.1186/1747-597X-7-25 (2012).
- Polygenic Risk Score Task Force of the International Common Disease, A. Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps. *Nat Med* **27**, 1876-1884, doi:10.1038/s41591-021-01549-6 (2021).
- Hollegaard, M. V. *et al.* Robustness of genome-wide scanning using archived dried blood spot samples as a DNA source. *BMC Genet* **12**, 58, doi:10.1186/1471-2156-12-58 (2011).
- Borglum, A. D. *et al.* Genome-wide study of association and interaction with maternal cytomegalovirus infection suggests new schizophrenia loci. *Mol Psychiatry*, doi:10.1038/mp.2013.2 (2013).
- 21 98 Illumina Gencall Data Analysis Software (Illumina, Inc., San Diego, 2005).
- 22 99 Korn, J. M. *et al.* Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs. *Nat Genet* **40**, 1253-1260, doi:10.1038/ng.237 (2008).
- 25 100 Goldstein, J. I. *et al.* zCall: a rare variant caller for array-based genotyping: genetics and population analysis. *Bioinformatics* **28**, 2543-2545, doi:10.1093/bioinformatics/bts479 (2012).
- 28 101 Lam, M. *et al.* RICOPILI: Rapid Imputation for COnsortias PIpeLIne. *Bioinformatics* **36**, 930-933, doi:10.1093/bioinformatics/btz633 (2020).
- 30 102 Schork, A. J. *et al.* A genome-wide association study of shared risk across psychiatric disorders implicates gene regulation during fetal neurodevelopment. *Nat Neurosci* 32 **22**, 353-361, doi:10.1038/s41593-018-0320-0 (2019).
- Loh, P. R. *et al.* Reference-based phasing using the Haplotype Reference Consortium panel. *Nat Genet* **48**, 1443-1448, doi:10.1038/ng.3679 (2016).
- Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G. R. Fast and accurate genotype imputation in genome-wide association studies through prephasing. *Nat Genet* **44**, 955-959, doi:10.1038/ng.2354 (2012).
- 38 105 Iglesias, A. I. *et al.* Haplotype reference consortium panel: Practical implications of imputations with large reference panels. *Hum Mutat* **38**, 1025-1032, doi:10.1002/humu.23247 (2017).
- 41 106 Price, A. L. *et al.* Long-range LD can confound genome scans in admixed populations.
 42 *Am J Hum Genet* **83**, 132-135; author reply 135-139, doi:10.1016/j.ajhg.2008.06.005
 43 (2008).
- 44 107 Zhou, W. *et al.* Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. *Nat Genet* **50**, 1335-1341, doi:10.1038/s41588-018-0184-y (2018).

1	108	Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases and
2		traits. Nat Genet 47, 1236-1241, doi:10.1038/ng.3406 (2015).

- Pasman, J. A. *et al.* GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. *Nat Neurosci* **21**, 1161-1170, doi:10.1038/s41593-018-0206-1 (2018).
- Walters, R. K. *et al.* Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders. *Nat Neurosci* **21**, 1656-1669, doi:10.1038/s41593-018-0275-1 (2018).
- Karlsson Linner, R. *et al.* Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million individuals identify hundreds of loci and shared genetic influences. *Nat Genet* **51**, 245-257, doi:10.1038/s41588-018-0309-3 (2019).
- 12 Liu, M. *et al.* Association studies of up to 1.2 million individuals yield new insights 13 into the genetic etiology of tobacco and alcohol use. *Nat Genet* **51**, 237-244, 14 doi:10.1038/s41588-018-0307-5 (2019).
- Schaid, D. J., Chen, W. & Larson, N. B. From genome-wide associations to candidate causal variants by statistical fine-mapping. *Nat Rev Genet* **19**, 491-504, doi:10.1038/s41576-018-0016-z (2018).
- 18 114 Kichaev, G. *et al.* Improved methods for multi-trait fine mapping of pleiotropic risk loci. *Bioinformatics* **33**, 248-255, doi:10.1093/bioinformatics/btw615 (2017).
- 20 115 Kichaev, G. *et al.* Integrating functional data to prioritize causal variants in statistical fine-mapping studies. *Plos Genet* **10**, e1004722, doi:10.1371/journal.pgen.1004722 (2014).
- 23 116 Kichaev, G. & Pasaniuc, B. Leveraging Functional-Annotation Data in Trans-ethnic Fine-Mapping Studies. *Am J Hum Genet* **97**, 260-271, doi:10.1016/j.ajhg.2015.06.007 (2015).
- 26 117 Benner, C. *et al.* FINEMAP: efficient variable selection using summary data from genome-wide association studies. *Bioinformatics* **32**, 1493-1501, doi:10.1093/bioinformatics/btw018 (2016).
- 29 118 Bennett, D. A. *et al.* Religious Orders Study and Rush Memory and Aging Project.
 30 *Journal of Alzheimer's disease : JAD* **64**, S161-S189, doi:10.3233/JAD-179939 (2018).
- Consortium, G. T. *et al.* Genetic effects on gene expression across human tissues.

 Nature **550**, 204-213, doi:10.1038/nature24277 (2017).
- Prive, F., Arbel, J. & Vilhjalmsson, B. J. LDpred2: better, faster, stronger. Bioinformatics, doi:10.1093/bioinformatics/btaa1029 (2020).
- Mullins, N. *et al.* Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. *Nat Genet*, doi:10.1038/s41588-021-00857-4 (2021).
- Trubetskoy, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature*, doi:10.1038/s41586-022-04434-5 (2022).
- 40 123 Levey, D. F. *et al.* Reproducible Genetic Risk Loci for Anxiety: Results From approximately 200,000 Participants in the Million Veteran Program. *Am J Psychiatry* 42 **177**, 223-232, doi:10.1176/appi.ajp.2019.19030256 (2020).
- Nagel, M., Watanabe, K., Stringer, S., Posthuma, D. & van der Sluis, S. Item-level analyses reveal genetic heterogeneity in neuroticism. *Nature communications* **9**, 905, doi:10.1038/s41467-018-03242-8 (2018).
- Therneau, T. M. & Grambsch, P. M. *Modeling Survival Data: Extending the Cox Model.* (Springer, 2000).

1	126	A Package for Survival Analysis in R, R package version 3.2-13 (2021).
2	127	Ge, T., Chen, C. Y., Ni, Y., Feng, Y. A. & Smoller, J. W. Polygenic prediction via
3		Bayesian regression and continuous shrinkage priors. Nature communications 10,
4		1776, doi:10.1038/s41467-019-09718-5 (2019).
5	128	Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and
6		richer datasets. <i>GigaScience</i> 4 , 7, doi:10.1186/s13742-015-0047-8 (2015).
7		

Table 1: Top 5 index SNPs for previous and top 15 index SNPs for novel MD GWAS loci. Results for the top 5 among previously identified loci and top 15 novel genome-wide significant index variants identified in the GWAS meta-analysis of 371,184 cases with Major Depression and 978,703 controls. The location (chromosome (Chr)) base position (BP)), alleles (A1/A2), odds ratio (OR) of the effect with respect to A1, standard error (SE) and association P-values (P) from inverse-variance weighted fixed effects model of the index variants are given. "Novel" indicates if the locus is a novel MD risk locus i.e. not identified previously. Genes located within 50 kb from index variants are listed (See supplementary table 2 for details on all 303 index SNPs)

Loc	$_{\mathrm{Chr}}$	$_{\rm indexSNP}$	BP	A1/A2	cases	ctrls	OR	SE	P	Nearby genes	Novel
8	1	rs7531118	72837239	T/C	0.473	0.461	0.97	0.0029	1.5e-27	NEGR1	no
9	1	rs10890020	73668836	A/G	0.508	0.510	0.97	0.0029	1.7e-21	LINC01360	no
38	2	rs1320138	144158287	T/C	0.428	0.435	1.02	0.0028	4.8e-09	ARHGAP15	yes
45	2	rs6715105	198445601	T/C	0.326	0.341	1.02	0.0030	1.3e-09	ANKRD44, ANKRD44-ITI, SF\$B1, COQ10B, HSPD1, SNORA105A, SNORA105B, HSPE1, HSPE1-MOB4, MOB4, RFTN2, MAR\$2, BOLL, PLCL1	yes
53	3	rs56029819	43478295	T/C	0.853	0.849	0.98	0.0040	2.5e-09	SNRK, SNRK-AS1, ANO10	yes
80	5	rs4262121	31078958	G/C	0.528	0.546	0.98	0.0029	4.3e-09	-	yes
89	5	rs62379847	120109119	A/C	0.655	0.652	0.98	0.0030	1.8e-09	PRR16	yes
93	5	rs2964003	153216733	A/G	0.829	0.820	1.02	0.0038	8.1e-10	GRIA1, LINC01861	yes
94	5	rs4596421	161269895	C/T	0.708	0.693	0.98	0.0031	2.4e-09	GABRA1	yes
98	6	rs35883476	28368508	G/C	0.910	0.918	1.05	0.0052	1.3e-21	HIST1 histone cluster, BTN3A2, BTN2A2, BTN8A1, BTN2A3P, BTN3A3, BTN2A1, LOC285819, BTN1A1, HCG11, HMGN4, LOC105374988, ABT1, ZNF322, GUSBP2, LINC00240, LOC100270746, MIR3143, PRSS16, POM121L2, VN1R10P, ZNF204P, ZNF391, ZNF184, LINC01012, LOC100131289, OR2B2, OR2B6, ZNF165, ZSCAN12P1, ZSCAN16-AS1, ZSCAN16, ZKSCAN8, ZNF192P1, TOB2P1, ZSCAN9, ZKSCAN4, NKAPL, ZSCAN26, PGBD1, ZSCAN31, ZKSCAN3, ZSCAN12, ZSCAN23	no
99	6	rs10947690	37631768	A/G	0.751	0.756	0.98	0.0033	6.3e-09	MDGA1	yes
114	7	rs957360	3660918	C/G	0.714	0.702	1.02	0.0031	1.3e-09	SDK1	yes
124	7	rs1986692	133743393	A/G	0.612	0.610	1.02	0.0029	2.8e-09	EXOC4	yes
156	10	rs1909696	77582203	G/T	0.337	0.328	0.98	0.0030	3.3e-09	LRMDA, LOC105378367	yes
158	10	rs1021363	106610839	A/G	0.349	0.335	1.03	0.0029	5.3e-25	SORCS3	no
191	13	rs9561331	94017476	G/A	0.869	0.873	0.98	0.0042	3.7e-09	GPC6	yes
199	14	rs7141014	98667928	T/C	0.796	0.806	0.98	0.0035	3.3e-09	•	yes
210	15	rs4886915	78075023	A/G	0.421	0.423	0.98	0.0028	6.1e-10	LINGO1	yes
225	17	rs60856912	65892343	G/T	0.825	0.817	0.97	0.0038	1.8e-11	BPTF, C17orf58, KPNA2	yes
233	18	rs12967143	53099012	G/C	0.301	0.292	1.03	0.0031	2.0e-21	TCF4, TCF4-AS1, MIR4529	no




Figure 1: Miami plots... (A) TWAS, genes are represented by both gene expression and isoform expression (= features, represented by the dots). A red line indicates Bonferroni corrected genome-wide significance within analyses; $p < 1.44 \times 10-6$; corresponding to Bonferroni correction of all the 34,646 features. The top transcript is labeled for each independent linkage disequilibrium block as previously described (PMID: 26395773). (B) Gene-based MAGMA analysis: A total of 268 significant genes were located in 93 of the 238 genomic risk loci identified using FUMA, while the remaining 143 significant genes were located outside these loci (table S7). The most significant gene within each of the 93 genomic risk loci are labeled in this plot. Gene names are labelled red if they overlap with the top gene within each independent locus of the TWAS in (A). (C) Manhattanplot of the meta-analysis GWAS of major depression (broad definition). Neighbouring index SNPs were considered independent when $r^2 < 0.1$ in a sliding 3 Mb window. For each index SNP we defined the associated LD-region by recording the left and rightmost variant with $r^2 < 0.1$. To define GWAS loci, a 50kb window was added on each side of the LD-region and overlapping LD-regions were combined into a single locus. Only a single SNP was kept from within the MHC region, due to extended linkage disequilibrium and a strong association signal of the MHC region (chr 6:25-35 Mb). (D) Joint p-values as implemented in GCTA-COJO ingreen, while original p-values are in shades of grey.




Figure 2: Association of MD-PGS with measures of cognitive abilities in the PNC cohort (N=4,973). Beta values (and 95% confidence intervals indicated as horizontal bars) from linear regression testing for the association of MD-PGS with the 15 neurocognitive measures listed on the y-axis. β values and FDR adjusted p-values are indicated.



Figure 3: MiXeR bivariate analysis. Venn diagrams showing MiXeR results of the estimated number of variants shared between MD and psychiatric disorders (with significant genetic correlations with MD) and phenotypes representing other domains with high genetic correlation with MD. Circles represent loci unique to MD (green) and unique to the phenotype of interest (blue) and corresponding overlapping (shared) loci. The number of shared variants (and standard errors) are shown in thousands. The size of the circles reflects the polygenicity of each phenotype, with larger circles corresponding to greater polygenicity. The estimated genetic correlation (r_g and 95% confidence intervals) between MD and each phenotype from LDSC is shown below the corresponding Venn diagram, with an accompanying scale (-1 to +1) with blue and orange representing negative and positive genetic correlations, respectively. Bivariate results for the following comparisons are shown: BIPxMDD , SCZxMDD , ADHDxMDD , ASDxMDD , ALDCUDxMDD , neuroxMDD , SmoInixMDD , EAxMDD , (see also Supplementary Table XXX).




Figure 4: Absolute risk and HRR of developing a second episode of depression stratified by MD-PRS deciles (A) and MD-SUM-PRS (B). Absolute risk and HRR of transitioning into bipolar disorder stratified by BP-PRS deciles (C) and BP-SUM-PRS (D). Absolute risk and HRR of transitioning into schizophrenia stratified by SZ-PRS deciles (C) and SZ-SUM-PRS (D). Absolute risk and HRR of transitioning into substance-use-disorder stratified by SU-PRS deciles (C) and SUD-SUM-PRS (D). MD-SUM-PRS, BP-SUM-PRS, SZ-SUM-PRS and SUD-SUM-PRS were calculated by adding PRSs for multiple phenotypes weighted by $\log(OR)$ with the aim of optimising prediction (see methods for details). See supplementary figures S15, S17, S18 and S19 for results based on all PRSs analysed in the current study.